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Many factors influence the survival of patients with breast cancer. Tumour 
biology is likely the most important; secondly, the treatment options and the 
response to the treatment. Individuals with the same stage and similar 
pathological diagnoses can experience different clinical courses. There are 
prognostic tools using clinical and tumour indicators, but most are not 
individualised. Molecular platforms for personalised medicine has since evolved 
and perhaps will provide better prognostication. 
 
In this thesis, we study prognostic factors and survival of Singaporean women 
with breast cancer and the potential for better prognostication in Singaporean 
women: 
 
1. To investigate the ethnic difference in survival between an Asian 
population and a Western population: Singapore and Stockholm.  
2. To investigate the ethnic difference in survival between different ethnic 
groups in Singapore: Chinese, Malays and Indians. 
3. To investigate the effects of biological factors of tumours on survival 
amongst the different ethnic groups in Singapore: effect of receptor status.  
4. To design and investigate the use of molecular tools to prognosticate 
breast cancer in Singapore: 
a. To validate a series of gene expression signatures that we had 
previously described in our local Asian breast cancer population. 
b. To design and validate the use of a custom molecular array as an 
adjunct tool in the prognostication of breast cancer in addition to 
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MAIN BODY OF THESIS 
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CHAPTER 1  INTRODUCTION & LITERATURE REVIEW 
 
1.1  Review of risk factors of breast cancer: prognostic and 
predictive factors 
 
Carcinoma of the breast is a major cause of worldwide morbidity and mortality in 
females. Incidence of breast cancer is driven by many well reported risk factors 
(Table 1) and some of these factors in addition have prognostic implications.  
 
 
Table 1 Risk factors of breast cancer 






Personal history of breast cancer 
Genetic risk factors 
 
Ethnicity 
BRCA1 and BRCA2 
 
Dense breast tissue 
Other genes 
 
Benign proliferative lesions with atypia 
ATM in ataxia-telangiectasia 
 
Atypical ductal hyperplasia (ADH)  
p53 and CHEK2 in Li-Fraumeni syndrome  
 
Atypical lobular hyperplasia (ALH) 
PTEN in Cowden syndrome 
 
Lobular carcinoma in situ 
CDH1 
 
Menstrual periods: early menarche, late menopause 
STK11 in Peutz-Jeghers syndrome 
 
Previous chest radiation 
  
Diethylstilbestrol exposure 




Oral contraceptive use 
 
Obesity 








Many factors influence the survival of patients with breast cancer; they include 
patient factors, stage of disease, tumour biology, and cancer treatment. However, 
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there is much variability as individuals with the same stage and similar 
pathological diagnoses can experience different clinical courses. Tumour biology 
is likely the most important; secondly, the treatment options and the response to 
the treatment. Breast cancer survival is driven by the variability of the patients 
and their tumours.  
 
Figure 1 Overview of the factors that affect breast cancer survival 
 
Axillary nodal status, age, tumour size, pathologic grade, and hormone receptor 
status are the established prognostic and/or predictive factors for selection of 
adjuvant treatments(1). Some factors, like a person's age and ethnicity, cannot 
be changed; while others such as lifestyle behaviours: smoking, drinking, 
exercise, diet, obesity and pregnancies are modifiable; and these may influence 
the risk of breast cancer, the tumour biology and hence influence survival (Table 
2).  
 
Breast cancer is commonly treated by various combinations of surgery, 
chemotherapy, radiation therapy, hormone therapy and targeted therapy via a 
multimodality approach. Selection of therapy is influenced by clinical and 




Table 2 Factors influencing breast cancer biology and response to treatment 
Patient Characteristics 
 
Steroid Receptors and regulated Factors 
Age at diagnosis 
 




Hormomal  Risk Factors  
 
Heat shock proteins 
   
Histopathologic Features 
 











Tumour Suppressor Genes 























Microvessel density  
  
VEGF  
      
 
1.2 Tumour Biology 
 
There is much genetic variation in breast cancer tumours resulting in a 
heterogeneous group of tumours. Different risk factors are associated with 
different tumour characteristics and they in turn influence and predict the 
response to certain therapy and hence the difference in outcome. Some of these 




Figure 2 Tumour differentiation resulting in tumour phenotype and treatment 
heterogeneity 
 
Hormonal receptor status 
 
The importance of steroid hormone receptors to the biology of breast cancer was 
recognised more than 40 years ago. Human breast cancers are dependent upon 
oestrogen and /or progesterone for growth and that is mediated through the ERs 
and PRs. ER and PR are both members of the nuclear hormone receptor family 
that includes the androgen and retinoid receptors. They are located in the 
cytoplasm and operate as ligand-dependent transcription factors. Attachment of a 
lipid-soluble hormone to the ligand-binding domain results in unmasking of the 
DNA-binding sites on the receptor, followed by migration into the nucleus, and 
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binding to specific hormone-responsive elements near the genes that are 
responsible for the physiologic actions of the hormone. 
Tumour expression of ER and/or PR can identify those most likely to benefit from 
endocrine therapy and due to this predictive value, measurement of these 
receptors has become routine in breast cancer management. While the predictive 
value of hormone receptor expression is well accepted, its prognostic importance 
has been a matter of debate for many years.  
 
The independent contribution of PR expression has been debated(2) but recent 
reports indicate that patients with ER-positive but PR-negative breast cancers 
have a worse prognosis than those with both ER and PR positive tumours (3; 4). 
However, the predictive value of PR expression remains controversial, but as PR 
positivity may be helpful in selecting patients with ER-negative breast cancer who 
might benefit from a highly effective and low toxicity treatment, endocrine therapy 
is usually recommended. ER-negative/PR-positive tumours are uncommon (2; 5; 
6).  
 
Population based studies have shown that compared to women with ER+/PR+ 
tumours, women with ER+/PR-, ER-/PR+, or ER-/PR- tumours experienced 
higher risks of mortality, which were largely independent of the various 





Figure 3 Breast carcinoma-specific survival is illustrated according to oestrogen 
receptor (ER) and progesterone receptor (PR) status. 




The goal of endocrine therapy is to prevent breast cancer cells from receiving 
stimulation from endogenous oestrogen. Ovarian ablation by radiation or surgery 
was standard therapy in the 1950s but over time, this has been replaced with 
pharmacologic endocrine therapy. This include blockade of the ER by selective 
ER modulators such as tamoxifen or suppression of oestrogen synthesis by 
luteinizing hormone-releasing hormone (LHRH) agonists and by aromatase 
inhibitors (AIs, e.g., anastrozole). Tamoxifen is used in premenopausal women 
and the benefits of adjuvant tamoxifen have been most clearly demonstrated in 
the EBTCG meta-analysis (9). While tamoxifen remains an option for 
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postmenopausal women, AIs are generally preferred as they are more effective 
in preventing cancer recurrence in the first two years after surgery (10) or An 
adjuvant treatment strategy incorporating an aromatase inhibitor (AI) as primary 
(initial endocrine therapy), sequential (using both tamoxifen and an AI in either 
order) or extended (AI after five years of tamoxifen) therapy reduces the risk of 
breast cancer recurrence compared to five years of tamoxifen alone (11). 
 
HER2 receptor status 
 
The HER2 receptor belongs to the epidermal growth factor receptor (EGFR) 
family of receptors controlling epithelial cell growth and differentiation (12; 13) 
and possibly angiogenesis (14; 15). Previously called HER2/neu, or ERBB2, 
amplification of HER2 gene or expression of its protein is seen in 18 to 20 per 
cent of human breast cancers (16; 17). HER2 overexpression is associated with 
high rates of disease recurrence and death in the absence of adjuvant systemic 
therapy (18; 19). It has been correlated with higher Scarff-Bloom-Richardson 
grade, younger age at diagnosis, and a comedo ductal carcinoma in situ 
component (20).  
 
Guidelines from the ASCO expert panel recommend against using HER2 
positivity purely as a prognostic factor, but strongly recommended its use as a 
predictive factor for response to specific therapies such as trastuzumab and 
lapatinib (2) as outcomes are heavily influenced by subsequent therapy; 
sensitivity to different types of chemotherapeutic agents and preferential use of 
anthracycline-based chemotherapy. HER2 positivity is associated with relative 
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resistance to endocrine therapies but this is not used to withhold endocrine 
therapy (2).  
 
Although HER2 positive tumours are associated with high grade and LVI 
positivity where prognostic effects had been seen in advanced cancer, in low-
grade, node-negative patients, HER2 significantly affects the survival in this 
otherwise very good prognostic group(21). 
 
‘Triple negative’ breast cancer 
 
The triple-negative phenotype where the tumours did not exhibit the ER, PR and 
HER2 receptor became important because of its relation to the basal-like subtype 
of breast cancer. Triple-negative breast cancers affect younger, non-Hispanic 
black and Hispanic women in areas of low SES. The tumours were diagnosed at 
later stage and were more aggressive, and these women had poorer survival 




Poorly differentiated tumours have long been known to pursue a more aggressive 
course than their well differentiated counterparts (23; 24). Until recently 
histological grading has not been accepted as a routine procedure, mainly 




Together with tumour size and nodal status, grade has been found to be the most 
important prognostic factors for long-term survival(19). The higher failure rate for 
patients with high-grade tumours was due to a larger number of failures in 




Lymphovascular invasion (LVI) is a widely recognized prognostic factor in lymph 
node-negative breast cancers (26). However, there are controversial data about 
its prognostic significance in lymph node-positive patients (27; 28). The presence 
of LVI was a stronger predictor of early recurrence than tumour grade in 
postmenopausal patients who received no adjuvant therapy (25). LVI should be 
considered in the therapeutic strategy as a decision making tool in the adjuvant 
chemotherapy setting 
 
1.3 Ethnic differences in breast cancer 
 
Factors that may differ between ethnic groups that need to be considered include 
genetic differences such as effects of ethnic differences on tumour biology and 
ethnic difference in response to treatment; as well as psychosocial differences 
between ethnic groups in seeking and accepting medical treatment. Prognostic 
and predictive tools are just as important for recommendations of treatment. 
 
Population based study of ethnic differences in breast cancer survival is limited 
except for those between Afro-American women, Asian-American women and 
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Caucasian American women. In the United States, Afro-American women are 
known to have a worse outcome compared with Caucasian American women. 
This has been attributed to increased diagnosis of late-stage breast cancers, 
which could be explained by delayed diagnosis reflecting the socioeconomic 
status, cultural beliefs, access to healthcare (29), and the proportion of oestrogen 
receptor (ER)-negative tumours in the Afro-American women (30). However, 
observed differences between tumour specimens obtained from Afro-American 
women and tumour specimens obtained from white women, independent of stage 
and age at diagnosis, indicated that race may be a determinant, or a surrogate 
for other determinants, of aggressive breast carcinoma and specific cell cycle 
defects (31). 
 
Hormonal factors and tumour biology 
 
The ethnic disparity in incidence, mortality and survival is evident in the United 
States, where breast cancer is predominantly a postmenopausal disease in the 
Caucasian American population (30; 32) but a premenopausal disease in Asian 
or non-Caucasian populations (33–35). ER and/or PR negativity has been 
correlated with premenopausal disease, black race, and poor prognostic factor 
groups while oestrogen receptor positivity has been associated with 
postmenopausal disease, white race, and favourable tumour characteristics (7). 
 
In US women diagnosed with breast cancer from 1992 to 1998, a positive ER 
was found in 81% of non-Hispanic Whites and in 66% of Afro-Americans (36). 
ER-negative breast cancer, however, seems to be influenced by parity and age 
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at first birth. Multiparity and early age at first birth were associated with reduced 
relative risk of ER + PR + tumours in many studies (37–41) although there were 
also reports that did not show significant differences in association of parity, age 
at first live birth, breastfeeding history, age at menopause, or synthetic hormonal 
use between molecular subtypes of breast cancer (42). It has been reported that 
increased parity at an early age is associated with ER-negative breast cancer 
(43). Early age at first birth could also have an adverse effect on the prognosis of 
breast cancer (40; 44) due to the interplay of hormonal factors in tumour biology 
and prognosis. More Afro-American women have children early (<20 years old) 
(45; 46) and tend to have higher parity compared with the non-Hispanic White 
women (47). Interethnic relations, including the influx of other migrant populations 
causing possible genetic complexities would not explain the rising cancer trend, 
because large-scale genetic mutations would manifest only after two to three 




Socioeconomic deprivation may be responsible for the increased risk of breast 
cancer mortality in African American and Hispanic patients, as they are more 
likely than white American patients to be diagnosed with advanced disease. 
Racial differences in breast cancer incidence can largely be accounted for by 
ethnic differences in SES among white, Hispanic and Asian/Pacific-Islander 
women, but not between these populations and black women (49). Stage at 
diagnosis, first course treatment and race explained most of the socioeconomic 
disparity in breast cancer survival (50; 51). Among white women, social 
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deprivation is related to poor breast cancer prognosis, with increased prevalence 
rates of high-grade, oestrogen receptor (ER)-negative tumours, similar to that of 
triple-negative breast cancers observed in African American and Hispanic women. 
Triple-negative breast cancers affect younger, non-Hispanic black and Hispanic 
women in areas of low SES(52). In a Detroit study population, race was not 
statistically significantly associated with unfavourable breast cancer outcomes. 
However, low SES was associated with late-stage breast cancer at diagnosis, 
type of treatment received, and death(53). A positive family history of breast 
cancer may reduce SES differences in access to screening and optimal 
treatment(54).  
 
However, the relationship of SES with breast cancer is not a simple one as it is 
intertwined with the risk of developing breast cancer. A large population study in 
Wisconsin showed that after controlling for individual education and other 
individual-level risk factors (age, mammography use, family history of breast 
cancer, parity, age at first birth, alcohol intake, body mass index, hormone 
replacement use, oral contraceptive use, and menopausal status), women living 
in the highest SES communities had greater odds of having breast cancer than 
women living in the lowest SES communities (55); there is a decrease in mortality 
rates of localized breast cancer as SES declined,  whereas regional breast 








Other factors such as diet, obesity, other behavioural, cultural and environmental 
known to affect incidence (38), has effects on prognosis that is less known (57); 
and these differences exist between ethnic groups. Diet for instance, soy intake 
amongst Chinese (58; 59) have been shown to decrease risk of death in Chinese 
women; but soy is not present in the western diet. Obesity is associated with 
advanced breast cancer at diagnosis, high tumour proliferation rates, and more 
triple-negative phenotypes, indicating that it may adversely contribute to 
prognosis (60). 
 
1.4 Relative survival ratio 
 
The most common measures in cancer are incidence, mortality, and survival. A 
statistical measure can be considered desirable if it reflects the underlying 
quantity of interest. A public health goal is to prevent the occurrence of cancer 
and doctors play a large part in these endeavours. The goal of the clinician is to 
reduce morbidity and mortality amongst those individuals who will experience 
morbidity and mortality due to cancer. To assess progress towards the goal of 
reducing cancer mortality we would ideally like to be able to measure cancer 
mortality amongst individuals who are destined to experience increased mortality 
due to cancer. From a clinical perspective, mortality amongst the patients is of 
greater interest. 
Relative survival ratios were computed by taking the ratio of observed survival to 




 Relative survival    = observed survival 
Expected survival 
 
Population mortality rates do not serve our purpose as they measure mortality in 
the entire population during a specified period of time. The published cancer 
mortality rates for a particular year are calculated by counting the number of 
deaths due to cancer amongst patients diagnosed over a period of many years, 
for some malignancies during several decades. The denominator includes the 
entire population, irrespective of whether or not they have been diagnosed with 
cancer. Mortality rates will therefore be subject not only to trends in cancer 
patient survival but also to trends in cancer incidence. As such, they are not an 
ideal measure of the progress in diagnosis and treatment of cancer.  
 
Estimates of patient survival are based upon ‘patients diagnosed with cancer’; 
not identical to ‘individuals who will experience increased mortality due to cancer’ 
but close. This difference between the desired study base and the actual study 
base should be kept in mind when interpreting the estimates(61).  
 
1.4 Descriptive epidemiology in Singapore 
 
Breast cancer trend 
 
Singapore is characterised by three main ethnic groups: Chinese, Malays and 
Indians. These three ethnic groups have remarkable differences in breast cancer 
incidence in spite of relatively similar changes in reproductive and socioeconomic 
changes. The overall incidence of breast cancer almost tripled from 22.0 per 
15 
 
100,000 in 1973-77 to 60.0 per 100,000 person years in 2005–2009(48; 62). It 
has continued to be the most common cancer among females; thus, it also 
comprised the greatest proportion of cancer deaths (63; 64).  
 
The increase in breast cancer incidence was different among the Chinese, 
Malays and Indians, as was previously reported (48). Singaporean Malay women 
in the earlier years had the lowest risk of developing breast cancer. However, 
Chinese and Malay women born in later birth cohorts had higher risks of 
developing breast cancer compared to their counterparts born in 1926–1930; the 
risk increase was sharper in the pre-menopausal Malays than in the Chinese.  In 
the last decade, the increase in breast cancer incidence was highest among the 
Malays; the age-standardised rate (ASR) increased from 44.8 to 58.7 per 
100,000 from 1998–2002 to 2005–2009(62). Among the Chinese, the ASR of 
breast cancer increased from 57.4 to 60.8 per 100,000 and 47.4 to 53.8 among 
the Indians in the same periods. However, the age-standardised mortality rate 
had remained fairly constant, at about 14 per 100,000 person-years in the period 
1998–2007(62).  
 
Although breast cancer was the most common cancer found among Singapore 
women, the prognosis was relatively optimistic. The five-year age-standardised 
RSR has remained at about 76% in the period of 1998–2002 to 2005–2009(62). 
Data from the Singapore breast screening pilot project in 1994–1997 as well as 
the nation-wide breast screening programme (BreastScreen Singapore) launched 
in Singapore in January 2002 (65) showed that breast screening is effective in 
allowing for cancers in less advanced stages to be detected and treated early, 
thereby improving the survival of breast cancer patients. More than 30% of pre-
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invasive ductal carcinoma in situ was detected among pre-menopausal women 
through the programme (66; 67). 
 
Socioeconomic Status 
Singapore underwent much economic restructuring in the 1980s and 1990s, 
resulting in marked economic improvements over these two decades (68) with an 
increase in Gross Domestic Product was 725% from 1980 to 1999 (International 
Monetary Fund statistics). This resulted in improved living standards, improved 
education and presumably better awareness of the disease, and in better 
healthcare including breast screening – albeit opportunistic. Singapore is a small 
island and enjoys a large network of affordable and easily accessible primary 
healthcare services that with heavily subsidized hospital and specialist care 
services. Healthcare indicators such as life expectancy, the infant mortality rate 
and the hospital to population ratio are comparable to developed countries like 
Sweden (69; 70).  
 
Using education and housing type as a surrogate for SES, Chinese have the 
highest SES;  more Malays were living in public housing (HDB, Housing 
Development Board), especially in the smaller 1-2-room flats, compared to the 
Chinese and Indians; and the Chinese and Indians tended to have higher 
education. Younger Singaporeans received higher education than older 
Singaporeans and this improved over the decade in all groups, signifying overall 
improvement in education. Although the proportion of Malays receiving higher 
education more than doubled over the decade, this was still less compared to the 






Total fertility by calendar year declined across the three ethnic groups, from over 
4,000 births per 1,000 women in the 1960s to around or less than 2,000 births 
per 1,000 women in the late 1990s. The Malays tend to have the highest total 
fertility rate, followed by the Indians and lastly the Chinese, with more than a third 
of Malay women having 3 or more children (Table 3). 
 
There was also an increasing trend in the age at first birth for the three ethnic 
groups. The median age at first birth in 1970 ranged from 21.6 to 24.9, while in 
2000, it ranged from 25.6 to 29.2. In 1970, the median age of first birth for Malay 
women was 21.6, compared to 24.9 for the Indians and 23.8 for the Chinese. By 
the year 2000, the median age had increased to 25.6 for the Malays, 29.2 for the 
Indians and 28.9 for the Chinese. The Chinese had the highest rate of increase 
over the 30 years period while the Malays consistently had the median youngest 
age at first birth (48). The impact of multiparity on premenopausal breast cancer 
risk differs across ethnic groups in Singapore. Increasing parity reduces the risk 
of premenopausal breast cancer in Malay, but not in Chinese and Indian women. 
Uniparous Malay women have twice the risk of premenopausal breast cancer 
compared to uniparous Chinese. This excess risk disappears after giving birth 
to >or=3 children. Indian women have lower premenopausal breast cancer risks 
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Culture and religion 
 
Cultural beliefs and attitudes in conjunction with SES could largely account for 
effect of race on breast cancer stage (72). Religion and culture are closely 
related and there is a difference between the ethnic groups. In 2010, 57 per cent 
of the Chinese identified themselves as Buddhists or Taoists, 20 per cent as 
Christians and 22 per cent as persons with no religion. Among the Indians, 
Hindus comprised 59 per cent, 22 per cent were Muslims and 13 per cent were 
Christians; while 99 per cent of Malays were Muslims (73).  
 
Diet and lifestyle 
 
Singapore offers a wide variety of culinary delights and much of this a direct 
consequence of the difference in cuisine between ethnic groups. Chinese women 
have a high intake of soy and consume the lowest amount of dietary fat (74) 
while Malay women are less likely to consume alcohol. Prevalence of obesity 
(BMI>/=30kg/m2) is highest  in Malay women (23.1%), compared to the Chinese 
(3%) and Indians (18.3%) as reported in the National Health Survey in 1998 (75).  
  
1.5 Comparison with other populations 
 
The ASR of breast cancer in Singapore is amongst the highest compared to the 
Asian counterparts, but lower than that in the USA and Europe(76). While the 
five-year ASR of breast cancer in Singapore was 60.0 per 100,000 person-years 
in 2005–2009, the corresponding ASR in Malaysia, China and India in 2008 were 
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37.0, 21.6 and 22.9 per 100,000 person-years, respectively; this was 76.0 per 
100,000 person years in USA correspondingly. In 2008, the age-standardised 
mortality rate of breast cancer in Singapore was comparable to that in Malaysia 
and the USA, but higher than that in China and India. The age-standardised 
mortality rates were 14.7, 5.7, 11.1 and 14.7 per 100,000 person-years for 
Malaysia, China, India and the USA, respectively(77). The five-year breast 
cancer survival in Singapore was lower than that in the USA (as represented by 
SEER) and China, but higher than that in India.(6) The five-year age-
standardised RSR of 76% in Singapore was slightly lower than that of countries 
in the Organisation for Economic Cooperation and Development (OECD) (81.2% 
in 2002–2007)(78). 
 
1.6 Prognostic tools 
 
The ‘ideal’ prognostic test 
 
Accurate prediction of survival is important in treatment recommendation 
following surgery for breast cancer. It allows clinicians to determine benefit from 
adjuvant therapy. A useful prognostic factor in breast cancer should have the 
following characteristics according to an NIH Consensus Conference (79): 
 
 Provide significant and independent prognostic value, validated by clinical 
testing 




 Results should be readily interpretable by the clinician 
 Measurement of the marker must not consume tissue needed for other 
tests, particularly routine histopathologic evaluation 
 
The current standard of care utilises a battery of assessments to prognosticate 
breast cancer, predict response to guide treatment. These include pathological 
factors that retain independent significance on multivariate analysis such as 
tumour size, tumour grade and lymph node status in addition to the efficacy of 
any adjuvant therapy; as well as predictive markers to treatment. However, these 
markers are associated with limits, including significant inter-observer variability 
and their reliance on measuring single biomarkers and hence the need to carry 




Tumour histological subtype, grade and LVI are standard histological features 
considered in the management of breast cancer. Each of these are subject to 
inter-observer variability(80) which results in inconsistencies in a proportion of 
cases. 
 
Assays for ER and PR status 
 
However, the methods of measurement have been fraught with variations that 
resulted in inaccurate test results due to variety of factors such as specimen 
handling, tissue fixation, antigen retrieval, and antibody type. In addition, 
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interpretation of the assay results is variable due to variable threshold values as 
well as inter-observer variations. These resulted in serious issues with ER 
reliability.  A joint committee representing ASCO and the College of American 
Pathologists (CAP) published guidelines that specifically address causes of 
variation related to measurement of ER and PR by IHC in 2010 (5; 6), which has 
become the predominant method of measuring ER and PR in clinical practice. 
The guideline recommendations include definition of appropriate specimen 
handling, fixation, analytical testing methods, thresholds for interpretation of 
positive and negative results, quality assurance methods, and monitoring 
strategies for individual laboratories.  
 
Assays for HER2 expression 
 
There are many ways to measure the activity of the HER2 oncogene; but the 
best method, in terms of the type of assay and the optimal method to perform 
each assay, is controversial. The available assays are: 
 HER2 gene amplification- Fluorescence in situ hybridisation (FISH), 
chromogenic in situ hybridization (CISH), silver-enhanced in situ 
hybridization (SISH) or differential polymerase chain reaction (PCR) 
 Overexpression of the HER2 protein product- Western blotting, enzyme-
linked immonosorbent assay (ELISA), or immunohistochemistry (IHC) 
 Overexpression of HER2 RNA- Northern blotting or reverse transcription 
PCR (RT-PCR) 
 
However, many of these methods have not been well standardized. Prospective 
sub-studies from adjuvant trastuzumab trials indicate that at least 20 per cent of 
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the HER2 assays performed locally were incorrect when the same specimen was 
re-evaluated in a high volume central laboratory (81–83). However, a high 
concordance was seen in central and reference laboratories (83). These highlight 
the importance of using high volume, experienced laboratories for HER2 testing 
to optimise the selection of patients most likely to benefit from trastuzumab. The 
joint committee representing ASCO and the College of American Pathologists 
(CAP) published guidelines that specifically address the technical and analytical 
aspects of HER2 testing (84). This committee recommended strict accreditation 
for laboratories providing HER2 testing and periodic proficiency testing.  
 
Clinical prediction models 
 
The current available clinical prediction systems include the Nottingham 
Prognostic Index (NPI) (85; 86), a prognostic scoring system using tumour size, 
grade and lymph node status; the web-based prognostication and treatment 
benefit tool Adjuvant! Online (87; 88) as well as the more recent Predict Tool (89; 
90) which uses a combination of clinical and pathological markers. However, 
these are based on the Surveillance, Epidemiology and End Results (SEER) 
registry and the Eastern Cancer Registration and Information Centre (ECRIC) 
respectively, which may limit their generalizability, especially in Asia. 
Adjuvant!Online’s prognostic performance validated in high income Caucasian 
populations, has recently been found to be over optimistic in middle income 





Molecular classification and prediction models  
 
Breast cancer profiling i.e., characterisation has significantly advanced over the 
past decade due to the development of sophisticated high throughput 
technologies, such as gene expression arrays that permit the simultaneous 
measurement of thousands of genes to create a molecular portrait of a tumour. 
Breast cancer tumour subtypes (92–95), expression signatures for clinical 
prognosis (96–98), ER/HER2 receptor status (99), and response to 
chemotherapy (100–102) have been established. Reassuringly, broadly similar 
molecular classes have been discovered (103) that are largely conserved across 
microarray platforms (104) and ethnic populations (105), and the reproducibility 
of gene expression signature–based predictions has been confirmed in replicate 
experiments (106; 107). Compared with conventional assays, molecular profiling 
platforms offer the potential advantage of measuring multiple biomarkers and 
signatures in a single test. These have been enthusiastically embraced by the 
scientific community and hailed as a major breakthrough on the way to 
individually tailored therapies.  
 





 Luminal A.  
 Luminal B. 
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The normal-like subtype was one of the initial subtypes identified and 
consistently appears in breast cancer clusters. It remains unclear whether it 
represents a separate subtype or a technical artefact due to a low tumour cell 
composition of the sampled specimen. Nevertheless, to establish the true 
clinical utility of molecular profiling, it is essential to validate such signatures 
in independent, prospectively defined patient cohorts (108) before accepting 
these new technologies in daily clinical practice. Although some profiling 
assays have recently undergone clinical validation (109; 110), these studies 
have been mostly done on U.S. and European cohorts (109; 111), and there 
is currently no similar project in Asia. Various clinical, epidemiologic, and 
molecular differences in breast cancer have been reported between different 
ethnic groups (32; 33; 105; 112–114), thus raising the need to assess the 
reliability of these signatures in an Asian cohort. 
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There are several multi-gene signatures in breast cancer available commercially, 
Table 4 (115), two such molecular tests merit specific comment. OncotypeDX 
(Genomic Health) is a RT-PCR-based assay that can be performed on formalin-
fixed tissue from paraffin blocks. It is based on the analysis of the expression of 
21 genes and provides a ‘recurrence score’ that correlates with outcome, as well 
(B) Kaplan–Meier analysis of 
disease outcome: time to 
development of distant metastasis 
in the 97 sporadic cases from van't 
Veer et al. Patients were stratified 
according to the subtypes as 
shown. Sorlie, T et al. Repeated 
observation of breast tumour 
subtypes in independent gene 
expression data sets. Proc Natl 
Acad Sca. USA 100, 8414-8423 
(2003) (103) 
(A) Sorlie T, et al. Gene expression patterns 
of breast carcinomas distinguishes tumour 
subclasses with clinical implications. Proc 
Natl Acad Sci USA 2001, 98:10869-
10874(91). 
The cluster dendrogram showing the five 
(six) subtypes of tumors are colored as: 
luminal subtype A, dark blue; luminal 
subtype B, yellow; luminal subtype C, light 
blue; normal breast-like, green; basal-like, 
red; and ERBB2+, pink. (B) The full cluster 
diagram scaled down (the complete 456-
clone cluster diagram is available as Fig. 4). 
The colored bars on the right represent the 
inserts presented in C–G. (C) ERBB2 
amplicon cluster. (D) Novel unknown cluster. 
(E) Basal epithelial cell-enriched cluster. (F) 
Normal breast-like cluster. (G) Luminal 
epithelial gene cluster containing ER 
Figure 4 Gene expression patterns of breast carcinoma 
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as likelihood of response to endocrine therapy and likelihood of response to 
chemotherapy(110; 111; 116; 117). Mammaprint (Agendia) uses expression 
array analysis of 70 genes to identify patients with good and poor prognostic 
signatures(109; 118; 119). This assay requires fresh frozen tumour tissue. It 
should be noted that, although both of these tests are already being used in 
patient management, their ultimate value will be determined by the results of 
prospective clinical trials that are currently underway, namely, the TAILORx trial 
to study OncotypeDX (117) and the MINDACT trial to study Mammaprint (119).  
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Table 4 Main features of the commercially available multi-gene signatures in breast cancer. 
 




CHAPTER 2  AIMS 
 
The aim of this thesis is to study the survival of breast cancer patients and the 




5. To investigate the ethnic difference in survival between an Asian 
population and a Western population: Singapore and Stockholm.  
 
6. To investigate the ethnic difference in survival between different ethnic 
groups in Singapore: Chinese, Malays and Indians. 
 
7. To investigate the effects of biological factors of tumours on survival 
amongst the different ethnic groups in Singapore: effect of receptor status.  
 
8. To design and investigate the use of molecular tools to prognosticate 
breast cancer in Singapore: 
a. To validate a series of gene expression signatures that we had 
previously described in our local Asian breast cancer population. 
b. To design and validate the use of a custom molecular array as an 
adjunct tool in the prognostication of breast cancer in addition to 




CHAPTER 3 STUDY 1: ETHNIC DIFFERENCE IN 
SURVIVAL BETWEEN STOCKHOLM AND SINGAPORE 
 
3.1  Subjects and Methods 
 
All cases of invasive breast cancer diagnosed from 1 January 1980 to 31 
December 1999 were obtained from the Singapore and Stockholm cancer 
registries (ICD 9: 174; ICD 10: C50). Patients with a previous malignancy, 
including contralateral breast cancer, and those diagnosed with breast cancer at 
autopsy (death certificate only) were excluded from the study. Follow-up was 
performed until 31 December 2005 by matching with the national death register. 
The cause of death was coded in accordance with the International Classification 
of Diseases and Causes of Death ICD9. The ethical committees at the National 
University of Singapore and Karolinska Institutet accepted the study without any 
restrictions. This is normal when de-identified material is used. 
 
Singapore Cancer Registry 
The Singapore Cancer Registry is a population-based registry that was started in 
1968. It receives voluntary notifications of incident cancers from all medical 
practitioners and pathology laboratories, as well as reviews, death certificates 
and hospital discharges for all patients. Staff of the Registry also reviewed cancer 
patient hospital discharges and death certificates. The completeness of reporting 
is high: 96% in the 1970s and close to 100% in the 1990s. The proportion of 
death-certificate-only notifications was 4.2% for the period 1968 to 1977, 1.0% for 
1993 to 1997 and 0.9% for 1998 to 2002 (120). Between 1980 and 1999, 10,287 
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female Singapore residents (citizens and permanent residents) diagnosed with 
breast cancer were identified and included in the study (120). 
 
Stockholm Breast Cancer Registry 
The Stockholm Breast Cancer Registry was started in 1977 and receives 
notification of newly diagnosed cases of breast cancer at all departments of 
oncology and surgery in Stockholm County, which is inhabited by 1.7 million 
individuals. There were 17,090 women diagnosed with breast cancer recorded in 




The stage of the breast cancer in the Singapore Cancer Registry was classified 
as localized cancer, regional spread and distant metastases based on the 
notification forms before 2001. Cancers are staged as local if they are confined 
entirely to the breast. Regional cancers are those that have extended beyond the 
limits of the breast directly into surrounding tissues or organs, or into lymph 
nodes in the region. Distant cancers are those that have spread beyond these 
locations. No attempt was made to access the extent of localized invasion or the 
number of regional lymph nodes involved. 
 
Stage information in the Stockholm registry was available according to the TNM 
staging system: tumour stage, lymph node stage and metastatic spread. This 
information was reclassified, using the Surveillance, Epidemiology and End 
Results Comparative Staging Guide for Cancer (121), to be comparable with the 
Singapore cohort – as localized disease where breast cancer was only identified 
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in the mammary gland; regional disease when there is direct extension to 
surrounding tissues or organs, or axillary lymph nodes are affected; and distant 
metastasis. 
 
The stage information from the cancer registry is a combination of clinical and 




Age at diagnosis was categorized into six age groups (<35 years, 35 to 44 years, 
45 to 54 years, 55 to 64 years, 65 to 74 years, 75+ years) and the period of 
diagnosis divided into two 10-year periods (1980 to 1989 and 1990 to 1999) to 
identify change over time; 1990 was selected because the early 1990s were 
when the use of tamoxifen became widely accepted and adjuvant treatment was 
more standardized in Singapore. 
 
Association of clinical variables between study groups were performed using chi2 
test, descriptive prognostic comparisons between Singaporean women and 
Swedish women were performed by relative survival analyses. Relative survival 
ratios were computed by taking the ratio of observed survival to expected survival, 
accounting for the competing causes of death.  
 
Relative survival    = observed survival 
Expected survival 
 
The expected survival probabilities were calculated using Ederer II method (122) 
derived from the general female population from Singapore and Stockholm, 
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respectively, similar to the breast cancer patients in terms of attained age and 
calendar period of diagnosis. In order to compare the survival between the two 
countries, cumulative relative survival ratios were age-standardized to the world 
standard cancer population (122). A 3-year central moving average for the 5-year 
relative survival ratios at each calendar year of diagnosis was used to depict the 
trend across the calendar periods. Joinpoint regression analysis was used to 
estimate the annual mortality trends from the five-yearly rates available for the 
Singaporean general population(123).  
 
A Poisson regression model was also used to calculate the excess hazards of 
death, taking into account the age, disease stage, period of diagnosis, country 
and years of follow-up. Interactions between country and the age of diagnosis, 
and between the calendar period and the age of diagnosis, were also analysed. 
Two age groups (</= 50 years old and >50 years old) were used to represent the 
premenopausal and postmenopausal age groups in this analysis. The incidence 
rates were calculated using the number of invasive breast cancer cases out of 
the total female population of each country for each time period. The cause of 
death information was used only to calculate the cause-specific mortality rate, 
which is the total of breast cancer deaths divided by the total female population of 
each country. Five-year incidence and mortality rates were reported and were 
age-standardized to the world standard population (123). STATA 8.2 (StataCorp. 









Table 5 presents the characteristics of the women in Singapore and Stockholm, 
diagnosed with breast cancer from 1980 to 1999. At the end of 2005, 9,330 (55%) 
of the Swedish women and 4,782 (46%) of the Singaporean women had died. As 
Chinese made up the majority of the Singaporean cohort, Chinese women were 
also studied as a separate group. The median age at diagnosis was stable within 
each country over the years of diagnosis; however, the Singaporean women 
were more than a decade younger than those in Stockholm. 
 
Stage information was only available for two-thirds of the Singapore cohort. The 
Swedish women were followed up for a median of 8.7 years (range 0.003 to 26.0 
years) while the Singaporean women were followed up for 7.7 years (range 0.003 




















   
Period of diagnosis 1980-1999 1980-1999 1980-1999 
Number of breast cancer cases 17090 10287 8663 
1980-1989 (%) 7932 (46) 3135 (30) 2661 (31) 
1990-1999 (%) 9148 (53) 7152 (70) 6002 (69) 
 
   
Median age at diagnosis  62 52 52 
Standard deviation 14 13 13 
Range( years)  18 - 101 12 - 98 17 – 98 
  Diagnosed < or = 50 years (%) 4247 (25) 5360 (52) 4472 (52) 
  Diagnosed >50 years (%) 12843 (75) 4927 (48) 4191 (48) 
 
   
Number of deaths (%) 9330 (55) 4782 (46) 3896 (45) 
Number of breast cancer deaths (%) 4050 (24) 2684 (26) 2159 (25) 
 
   
Number of women with information 
on stage* (%) 
16869 (99) 6569 (64) 5544 (64) 
1980-1989     
Local cancer (%) 6047 (77) 1090 (48) 953 (50) 
Regional cancer (%) 1667 (21) 961 (43) 804 (42) 
Distant cancer (%) 165 (2) 196 (9) 155 (8) 
1990-1999    
Local cancer (%) 7387 (82) 2283 (53) 1977 (55) 
Regional cancer (%) 1358 (15) 1692 (39) 1393 (38) 
Distant cancer (%) 245 (3) 347 (8) 262 (7) 
 
   
Estrogen receptor status    
Positive 9874 (77) not available not available 
Negative 2984 (33) not available not available 
     
* Invasive cancers are local stage if they are confined entirely to the breast. 
Regional cancers are those that have extended beyond the limits of the breast 
directly into surrounding tissues or organs, or into lymph nodes in the region. 





Figure 5 Overall age-standardized relative survival of women diagnosed with 
breast cancer from 1980 to 1999 in Singapore and in Stockholm in relation to 
time since diagnosis 
 
The overall relative survival for women diagnosed with breast cancer from 1980 
to 1999 appeared better for the Swedish cohort, where the Swedish women 
constantly outperformed the Singaporean women at each year of follow-up 
(Figure 5). The overall age-standardized 5-year relative survival for Singaporean 
women and for Swedish women was significantly different at 70% and 82%, 
respectively. The Singaporean Chinese has an overall age-standardized 5-year 
relative survival in between at 76% (Figure 5). However, the overall age-
standardized 10-year relative survival of the Singapore Chinese women 




























Years since diagnosis 
Age-standardized RSR by Country 
Stockholm Singapore Chinese Singapore
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Table 6 Overall and 5-year age standardized relative survival of women with 







Registry (Chinese) Characteristic 
5-year survival rates % 95% CI % 95% CI % 95% CI 
Overall observed survival 74 72 - 75 64 62 - 67 66 63 - 68 
Overall relative survival  82 80 - 83 70 67 - 73 76 73 - 79 
             Specific 5-year relative survival 
           Local 
            1980-1989 88 85 - 91 81 71 - 89 86 75 - 94 
1990-1999 88 85 - 90 90 85 - 95 99 92 - 105 
Regional 
            1980-1989 58 51 - 65 47 37 - 57 50 38 - 61 
1990-1999 64 57 - 71 68 61 - 75 74 65 - 82 
Distant  
            1980-1989 19 6 - 37 21 8 - 39 26 10 - 49 
1990-1999 21 9 - 37 28 17 - 42 33 18 - 49 
                          
 
 
Survival by stage 
 
The majority of Swedish patients were diagnosed with a localized cancer while 
only about one-half of the Singaporean women had localized cancer (Table 5). 
Over the past 20 years there has been a small increase in women presenting 
with localized disease with a larger corresponding decrease in regional disease 
in the Singaporean women; the proportion of metastatic cases remained fairly 
constant (Table 5). When all of the women diagnosed in 1980 to 1999 were 
stratified by the stage of breast cancer, there was no difference in the relative 
survival between the two countries, though the Singaporean Chinese appear to 




Figure 6 Age-standardized relative survival of women diagnosed with breast 
cancer from 1980 to 1999 in Singapore and in Stockholm by the stage of cancer 




Survival by period of diagnosis 
 
The 5-year age-standardized relative survival ratio was used to compare the 
survival by the period of diagnosis between the two cohorts. In the 1980s the 
Singaporean women showed an improvement in survival across all stages, most 
marked in those with regional disease (with improvement of almost 20%); a 
smaller improvement was seen in the Swedish women with the same stage. 
Singaporean women diagnosed with local cancer and regional cancer had poorer 
survival than the Swedish women (Table 6 and Figure 8). In the 1990s survival 
among the Singaporean women with localized cancer and regional cancer 
improved and was comparable with the Swedish women. In addition, these 
Singaporean women with local cancer showed a marginal survival advantage 
over the Swedish cohort in the later period. 
 
Survival by age group 
 
Singaporean women were diagnosed with breast cancer earlier in life than the 
Swedish women; they were on average 10 years younger. While 52% of the 
Singaporean women diagnosed with breast cancer were 50 years old or younger, 
only 25% of the Swedish women were 50 years old or younger (Table 5). Over 
the two decades, the median age in the Stockholm women decreased from 64 to 
61 years while it remained stable at 50 years old for the Singaporean women. 
The prognostic outlook was more optimistic for women with breast cancer when 






Figure 7 Five-year age-standardized relative survival of women with breast 
cancer in Singapore and in Stockholm by the stage of breast cancer and the 







Figure 8 presents the risk of death of the women taking age, disease stage, and 
period of diagnosis and years of follow-up into account in each country. As 
expected, the stage of cancer is an important predictor of survival. The risk of 
death was decreased in the later period for both countries and improvement was 
greater in the Singaporean women. As there was a significant interaction 
between the age at diagnosis and the period of diagnosis (p = 0.008), 
comparison between the two populations was performed stratified by the age and 












RR 95% CI p value 
 
RR 95% CI p value 
 
RR 95% CI p value 
Year of follow-up 









1.32 1.14 1.51 <0.0001 
 
1.36 1.15 1.60 <0.0001 
 
1.69 1.47 1.94 <0.0001 
3 
 
1.21 1.04 1.40 0.013 
 
1.25 1.05 1.49 0.014 
 
1.90 1.65 2.18 <0.0001 
4 
 
1.12 0.95 1.31 0.178 
 
1.17 0.97 1.41 0.106 
 
1.71 1.48 1.98 <0.0001 
5 
 
0.96 0.81 1.14 0.631 
 
0.98 0.80 1.21 0.859 
 
1.84 1.59 2.14 <0.0001 
Age group 









0.65 0.54 0.78 <0.0001 
 
0.67 0.54 0.84 <0.0001 
 
0.71 0.57 0.88 0.002 
45-54 
 
0.66 0.55 0.79 <0.0001 
 
0.70 0.57 0.87 0.001 
 
0.56 0.45 0.69 <0.0001 
55-64 
 
0.91 0.75 1.10 0.314 
 
0.95 0.76 1.19 0.675 
 
0.60 0.49 0.74 <0.0001 
65-74 
 
0.77 0.62 0.96 0.022 
 
0.71 0.54 0.94 0.016 
 
0.78 0.64 0.96 0.019 
75+ 
 
1.06 0.81 1.39 0.673 
 
0.79 0.54 1.14 0.201 
 
0.89 0.71 1.10 0.281 
Stage 









3.66 3.22 4.17 <0.0001 
 
4.18 3.57 4.89 <0.0001 
 
4.02 3.66 4.41 <0.0001 
Distant 
 
13.29 11.41 15.48 <0.0001 
 
15.19 12.64 18.26 <0.0001 
 
17.25 15.09 19.71 <0.0001 
Period of diagnosis 









0.53 0.48 0.58 <0.0001 
 
0.50 0.45 0.56 <0.0001 
 
0.91 0.83 0.99 0.027 




Table 8 Poisson regression: excess risk of death between countries stratified by 
age and period of diagnosis 
  
RR 95% CI p value 
 





Age <=50     
 
    
Country* 
         Stockholm 1.00 (reference) 
  
1.00 (reference) 
 Singapore 1.26 1.08 1.47 0.003 
 
0.81 0.70 0.94 0.007 
Age >50 
         Country*  
         Stockholm 1.00 (reference) 
  
1.00 (reference) 
 Singapore 1.48 1.29 1.69 <0.0001 
 
0.78 0.68 0.89 <0.0001 





Age <=50     
 
    
Country* 
         Stockholm 1.00 (reference) 
  
1.00 (reference) 
 Singapore (Ch) 1.15 0.98 1.36 0.085 
 
0.70 0.60 0.83 <0.0001 
Age >50 
         Country*  
         Stockholm 1.00 (reference) 
  
1.00 (reference) 
 Singapore (Ch) 1.30 1.12 1.51 0.001   0.64 0.55 0.75 <0.0001 
          
*Adjusted for year of follow up and stage 
      Ch: Chinese 
          
 
Interaction and effect modification 
 
As there was a significant interaction between the age at diagnosis and the 
period of diagnosis (p = 0.008), comparison between the two populations was 
performed stratified by the age and period of diagnosis (Table 8) to show the 




In 1980 to 1989 premenopausal Singaporean women had 26% increased risk of 
death compared with the women in Stockholm, adjusted for stage and year of 
follow-up, while the postmenopausal women had 48% increased risk. In 1990 to 
1999 the Singaporean women experienced a decreased risk of death of 19% and 
22%, respectively, for the premenopausal women and the postmenopausal 
women compared with the Swedish women; Comparison with the Singapore 
Chinese women showed a decreased risk of death of 30% and 36% (Table 8). 
 
In Stockholm, survival improved only in the premenopausal women over the two 
decades (hazard ratio = 0.74, P < 0.001). In Singapore, the improvement was for 
all women over the same period (hazard ratio = 0.51 and hazard ratio = 0.54 for 
premenopausal women and postmenopausal women, P < and P < 0.001, 
respectively; data not shown). 
 
 
Survival in comparison with incidence and mortality rates  
 
The incidence rate of breast cancer in Singaporean women has more than 
doubled during the period of study (1980 to 1999). In contrast, the increase in 
incidence in the Swedish women was only modest. The 5-year cause-specific 
mortality rate was constant in the Singaporean women from 1985 to 1999 (Figure 
8). The mortality rate for the Swedish women also remained relatively constant 
over the period. The marked improvement in relative survival in the Singaporean 
women over the two decades is consistent with the discrepancies of the 




Figure 8 Trends in incidence, 5-year cause specific mortality and 5-year age-
standardized relative survival rates in patients with breast cancer in Singapore 
and Stockholm across calendar year of diagnosis 






The effect of ER status in the Stockholm population 
 
The ER status of the Singaporean population was not available for comparison. 
Study of the effect of ER-positive tumours within the Stockholm population 
showed the survival advantage (Table 9 and Figure 9) 
 
Table 9 Poisson regression: excess risk of death for women in Stockholm 
  
        
  
RR 95% CI p value 
Year of follow-up 
    1 
 
1.0 (reference) 
  2 
 
3.2 2.6 4.1 <0.005 
3 
 
3.8 3.0 4.9 <0.005 
4 
 
3.4 2.7 4.3 <0.005 
5 
 
3.7 2.9 4.7 <0.005 
      Age group 
    <35 
 
1.0 (reference) 
  35-54 
 
0.7 0.5 0.9 0.006 
45-54 
 
0.6 0.4 0.7 <0.005 
55-64 
 
0.6 0.5 0.8 <0.005 
65-74 
 
0.8 0.7 1.1 0.174 
75+ 
 
0.8 0.6 1.1 0.145 
      Stage 
     Local 
 
1.0 (reference) 
  Regional 3.1 2.8 3.5 <0.005 
Distant 20.8 15.8 27.5 <0.005 
      Period of diagnosis 
    1980-89 1.0 (reference) 
  1990-99 0.9 0.8 1.0 0.208 
      ER status 
    ER positive 1.0 (reference) 
  ER negative 2.6 2.4 2.9 <0.005 





Figure 9 Age-standardized relative survival of women diagnosed with breast 
cancer from 1980 to 1999 in Stockholm by ER status and stage of cancer in 






Internal validity can be defined as the absence of systematic errors within the 
study. The classification of systematic errors is not clear cut, but may be 
classified as bias and confounding. Systematic errors are not affected by sample 
size, which is different from random variable, which is reduced with increased 
sample size.   
Intermediate factors are factors caused by the exposure and causing the 
outcome and are not confounders. Tumour characteristics are considered 
intermediate factors between exposure and breast cancer deaths. 
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Interaction refers to factors acting together (synergistic or antagonistic) on the 
outcome. Compared to the main effects in a study, interaction between two 
variables always have a much lower power (124).  
Precision is a measure of random errors, the influence of chance that leads to 
uncertainty of the estimates found in a study. Precision is improved with increase 
in sample size.  
External validity is the possibility to generalise the finding to other populations 
than the one under study. The first requirement is internal validity and enough 
precision; it depends on the knowledge on or assumptions of biological 




This is a population based observational or cohort study. Generally, cohort 
studies are expensive and time-consuming for rare-outcomes requiring exposure 
information on a large number of individuals to obtain an adequate number of 
persons with the outcome of interest. Population register based studies however 
overcome this drawback of cohort studies; being rather cheap and covering 
significantly more patients (e.g. over 10,000 for a single site) followed for a long 
period. It gives good power to address the question of prognosis in relation to the 






Bias may be defined as any systematic error that results in an invalid estimate of 
the association between exposure and outcome of the disease. It is caused by 
faulty design and/or deficient execution of sampling process. 
Selection bias: Study Population and Cancer Registries 
The strengths of the study 1 include the large number of cases, from population-
based registries that report high levels of reliability (120; 125). This reduces the 
issues of selection bias in smaller cohort studies. Women in both countries have 
individual unique national registration numbers as citizens and permanent 
residents that allow for accurate personal data collection. Women with bilateral 
breast cancers or multiple cancers can be excluded from the study. The study 
also extends over two decades, which was probably long enough to observe 
differences and allow the study of trends. Women with a previous malignancy, 
including contralateral breast cancer, and those diagnosed with breast cancer at 
autopsy (death certificate only) were excluded from the study to remove the bias 
these factors may cause. 
 
Time bias with Breast screening 
Survival time is measured from the date of diagnosis to the date of death; 
however, diagnosis does not occur at the same point in the natural history for 
every patient, so care is required when interpreting survival estimates. Earlier 
diagnosis by screening can cause lead-time bias and falsely depict better 
survival, where the time of diagnosis was earlier while the death from breast 
cancer was not delayed or avoided. Without a nationwide breast screening 
program in Singapore, the lead-time bias could not be an advantage for 
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Singapore to explain the decreased risk of death for 1990 to 1999. Opportunistic 
screening is available and widely used in clinics, however, as healthcare and 
health awareness improved with the socioeconomic status of Singapore in the 
1990s. Length-time bias may exist and is a limitation in this comparison since 
screening is probably more extensive, having been implemented early in 
Stockholm. We would expect a more favourable outcome in the Swedish 
population when a greater proportion of slow-growing breast cancer with good 
prognosis is being diagnosed (126). This is difficult to quantify without a 
randomized trial. Cultural differences amongst ethnic groups in Singapore may 
also contribute towards response to breast screening and hence result in 
differences in stage distribution of breast cancer amongst the ethnic groups (see 




Associations between a variable and outcome can be affected by a third variable, 
a confounder. The confounder must be a risk factor of the outcome associated 
with the exposure variable, and not caused by the exposure or outcome. 
Confounding factors such as registry completeness, stage migration and 
distribution and diagnostic improvements have to be considered when analysing 
trends in cancer survival. As ethnicity can be an important confounder for 





Stage and clinical information 
Incomplete disease stage information for one-third of women in Singapore is a 
limitation of the study. To our knowledge, every effort has been put in to ensure 
the completeness of cancer reporting over the years. Clinical staging information, 
which used to be reported voluntarily, could contribute to the lack of information. 
There is now a follow-up mechanism by the registry, however, to obtain detailed 
clinical information from the clinical case notes. The proportion of unknown 
disease stage was hence worst in the early 1990s, only 52% with complete 
clinical staging for cases in 1990 to 1994 (p < 0.001), and this improved in the 
last 5 years of the study. This incomplete staging is probably random; however, 
as the age-standardized survival for the Singaporean women with unknown 
disease stage was comparable with the overall survival of those with stage 
information (data not shown). The ethnic distribution between the two groups was 
not different (p = 0.576), and the age distribution by the period of diagnosis was 
also similar except for fewer women between 35 and 54 years old being 
diagnosed in 1985 to 1989 (p = 0.032). 
 
The accuracy of staging could have affected the stage distribution and should 
be regarded with caution. It is possible that, in the earlier years, node-positive 
tumours were underdiagnosed and falsely classified as being localized, and 
hence appeared to have poorer survival. The axillary dissection and histologic 
assessment of specimens may have been less thorough. The proportion of such 
cases is unknown in this study, but is probably small. Active screening for distant 
metastases at the time of initial diagnosis, a practice routinely adopted in 
Singapore but not in Sweden, can induce stage migration and increase the 
stage-dependent survival in all stages to the benefit of the Singaporean women; 
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Sweden has a relatively homogenous in its ethnicity of white Europeans while in 
Singapore, Chinese form a majority of about 80 per cent of the population. As 
ethnicity can be an important confounder for population comparisons, a 
comparison with Singaporean Chinese was made with the Stockholm population. 
This showed a slight improved survival amongst the Chinese population 
compared to the general population.  
 
Others factors 
Treatment information is not available in the study 1. This is also a limiting factor 
as confounding due to differences in treatment between the groups may impact 
the survival outcome. Other factors such as body mass index, diet, and other 
behavioural, cultural, environmental, or genetic differences are factors that have 
been known to affect incidence (38), but the effect on prognosis is less known 
(57), and is not available in these studies. Singapore, however, reported fewer 
women who smoke 3.2% (2004 National Health Survey statistics)  (127) 
compared with 29% of Swedish women in 1980, and 18% in 2005 (Sweden 
statistics). Only about 6% of postmenopausal women in Singapore are on 
hormonal replacement therapy for menopause (128), compared with 21% of 
women in Sweden (129). Obesity (BMI > 30kg/m2) was approximately 10 % of 
women in Sweden in a 2006 report (130) and 6 % of the population in Singapore 
(2004 National Health Survey statistics) (127). Alcohol consumption reported to 
be 0.3% in women in Singapore (2007 National Health Survey statistics). 
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Study of survival trends 
 
Relative survival has become the preferred measure for the analysis of patient 
survival based on data from population-based cancer registries. The relative 
survival ratio (RSR) is defined as the observed survival in the patient group 
divided by the expected survival of a comparable group from the general 
population, matched to the patients with respect to the main factors affecting 
patient survival and assumed to be practically free of the cancer of interest. 
 
The strength of the relative survival ratio is that it provides a measure of the 
excess mortality experienced by patients diagnosed with cancer, irrespective of 
whether the excess mortality is directly or indirectly attributable to the cancer. An 
advantage of this measure is that information on cause of death is not required; 
thereby circumventing problems with the inaccuracy or non-availability of death 
certificates. This method is preferable when cause of death classification is 
unreliable, but this was not a likely issue with our studies. Similar to all-cause 
mortality, this is inferior compared to cause-specific death when the cases are 
expected to have a different overall mortality than the base population.  However, 
most women in the studies died from breast cancer, hence competing risks are 
not likely to influence the results.  
 
As advocated by Dickman and Adami, the trends in survival were interpreted in 
context with the incidence and mortality rates to evaluate the progress against 
cancer (61). The marked improvement in relative survival in the Singaporean 
women over the two decades is consistent with the discrepancies of the 
incidence and mortality rates described. 
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Effects of Stage distribution 
 
The observation of the overall survival advantage in Stockholm (Figure 1.1) 
occurs because the proportion of women diagnosed with a local cancer (80%) 
was larger than that of Singaporean women (51%), (Table 1.1). This larger 
diagnosis is a consequence of established organized mammographic screening 
in Sweden since the late 1980s, which became nationwide in the mid-1990s. This 
advantage was present throughout the study period as more Swedish women 
were consistently being diagnosed with localized disease (Table 1.1). The effect 
of stage distribution being a key reason for the difference in survival of the 
Singaporean population compared with the Stockholm population is reminiscent 
of a study from Stockholm in the period 1961 to 1973 (131), and is again 
reflected in a later comparison of screened and non-screened Danish and 
Swedish populations (132). This survival advantage of the women in Stockholm 
disappeared when the observations are stratified by stage, with the Singaporean 
women enjoying better survival in the later years of diagnosis. 
 
Effects of Period of diagnosis 
 
When compared across the period of diagnosis in the study, there was a 
consistent overall decreased risk of death. There was decreased risk of death in 
the premenopausal women in both populations and in the postmenopausal 
women in Singapore, signifying improvements in both countries. In the later 
period where nationwide screening was still not present in Singapore, the 
Singaporean women were performing no worse than the Swedish women (Figure 
1.3). Interestingly, after adjusting for potential confounders, there was a mean 19% 
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(CI 6% to 30%) decrease in risk of death in the premenopausal and a mean 22% 
(CI 11% to 32%) decrease in the postmenopausal Singaporean women as 
compared with Swedish women during the period 1990 to 1999 (Table 1.4).  
 
Improved health care services 
 
A significant change in Singapore during the study period is that Singapore 
underwent much economic restructuring in the 1980s and 1990s, resulting in 
marked economic improvements over these two decades (68). The increase in 
Gross Domestic Product was 725% in Singapore and 190% in Sweden from 
1980 to 1999 (International Monetary Fund statistics). This resulted in improved 
living standards, improved education and presumably better awareness of the 
disease and better healthcare including breast screening – albeit opportunistic – 
in Singapore.  
 
Like Sweden, Singapore enjoys a large network of affordable primary healthcare 
services that refer to government-funded (Sweden) or heavily subsidized 
(Singapore) hospital and specialist care services. Healthcare indicators such as 
life expectancy, the infant mortality rate and the hospital to population ratio are 
comparable (69; 70). This coincided with a time trend towards less advanced 
tumours being diagnosed, where a small but definite increase in women with 
localized disease and a corresponding decrease in women with regional disease 
over the study period was observed in Singapore (Table 1.1). This is also 
supported by the finding of an increase in incidence of ductal carcinoma in situ 
from 0.4% in 1983 to 1989 to 8.1% in 1999 (Singapore Cancer Registry statistics), 
an indicator of increased mammographic screening.  
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As compared with the Swedish women who had enjoyed a more stable economy 
during this period, the small increase in incidence of localised breast cancer in 
Singapore was probably the result of initiation of screening practices that came 
with increased awareness, better education, and better healthcare facilities as 
our economy improved, to a greater benefit for the Singaporean women, even 
without a national screening program. 
 
Better breast cancer therapies 
 
Anti-oestrogen treatment has been well established since the 1990s. Seventy-
seven per cent of the Swedish women had tumours that were positive for the ER. 
This is in contrast to a report of 55% Singaporean women from a local institution 
(133) in 2007. The Swedish women would be expected to perform better in each 
stage if the receptor status was indeed stage independent. Although the survival 
advantage for the Swedish women with ER-positive tumours, the present study 
could not demonstrate the postulated survival advantage of ER-positive tumours 
between the two populations, or perhaps the effect of this factor is small. 
Nevertheless, the improvement of survival only in the premenopausal Swedish 
women across the period is probably the result of increased aggressiveness in 
treating this group of women, with tamoxifen (134) as well as chemotherapy. 
 
In addition, the improvement in survival in each stage across the periods – 
including for those with distant metastasis, albeit small (Figure 1.3 and Table 1.2) 
– would suggest improvement in treatment options with the use of adjuvant 
therapy with anti-oestrogen and chemotherapy that had become more 
standardized in the 1990s in Singapore. The quality of the healthcare and 
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treatment routines probably did not differ to a larger extent or to the benefit of 
Swedish women in the later part of the follow-up period. Treatment details are not 
available for these patients and are a study limitation. Treatment of breast cancer, 
however, was standardized under institutional practice in both Stockholm and 
Singapore in the 1990s, and this was comparable (personal communication with 
P Hall, Stockholm, and CY Wong, Singapore). The survival equivalence after 
stratification by stage (Figure 1.2) suggests that both Singaporean women and 
Swedish women respond similarly to the treatments given. 
 
The relatively stable mortality and the corresponding marked increase in the 
survival ratios in the Singaporean women probably represented improved 
treatment options. The more superior survival ratios in the earlier years of 
diagnosis in the Swedish women remained relatively stable, while the increase in 
incidence coincided with a less dramatic change in the survival compared with 




Sweden has a relatively homogenous in its ethnicity of white Europeans while in 
Singapore, Chinese form a majority of about 80 per cent of the population. Until 
the 1970s Singaporean women had a mean fertility rate of approximately five 
children compared with two children for Swedish women (44). This higher fertility 
in the earlier Singaporean birth cohort contributed to the low incidence of breast 
cancer, especially postmenopausal breast cancer. Unfortunately, this may have 
resulted in a higher proportion of premenopausal breast cancer (Table 1.1), 
which is more likely to be ER-negative with poorer survival. Parity may therefore 
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not only affect risk (43; 135–137), but also the prognosis of breast cancer. This 
study is limited by the absence of information of the tumour receptor status as 
well as the unavailability of complete parity information in the Singaporean cohort. 
Although after adjusting for stage, age and period of diagnosis, the survival 
between this two ethnically different populations were not largely different. It 
remains unsettled whether risk factors of breast cancer that influence the cancer 
incidence and malignant phenotype will affect the prognosis.  
Information of risk factors such as BMI, other behavioural habits such as smoking 
and alcohol, HRT, environmental factors and menstrual history were not available 
in these studies. However, the incidence of obesity, HRT, alcohol consumption 
and smoking were known to be low in Singapore and less likely to influence the 
tumour biology and survival.  
 
Future studies could include using a more recent cohort where both populations 
are relatively stable in the economy, and when therapy for breast cancer is 
standardized, as well as inclusion of other risk factors of interest such as tumour 




The survival of women with breast cancer in each disease stage was comparable 
between the Singapore and Stockholm cohorts. Better economic status 
associated with increased awareness of the disease, better access to screening 
routines or healthcare quality and options, seen in Stockholm and in Singapore 
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CHAPTER 4 STUDY 2: SURVIVAL OF SINGAPOREAN 
WOMEN WITH BREAST CANCER: ETHNIC DIFFERENCES 
 
4.1 Subjects and Methods  
 
All cases of invasive breast cancer diagnosed from 1 January 1968 to 31 
December 2006 were obtained from the Singapore Cancer Registry, National 
Registry of Diseases Office (NDRO). Patients with a previous malignancy, 
including contralateral breast cancer, and those diagnosed with breast cancer at 
autopsy (death certificate only) were excluded from the study. Follow-up was 
performed until 31 December 2008 by matching with the national death register. 
The cause of death was coded in accordance with the International Classification 
of Diseases and Causes of Death ICD9. The ethical committee at the National 
University of Singapore accepted the study without any restrictions. This is 
normal when de-identified material is used. 
 
For the comparison between ethnic Chinese, Malays and Indians in Singapore, 
20517 women diagnosed between 1968 and 2006 were included in the study. 






Table 10 presents the characteristics of the Singaporean women diagnosed with 
breast cancer from 1968 to 2006 with follow up till 31 December 2008. At the end 
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of 2008, 7937 (39%) women had died. The Malay women tended to be younger 
and were diagnosed in a later stage compared to the Chinese and Indians.  
 
Table 10 Characteristics of Singaporean breast cancer cohort by ethnicity 
Characteristic Chinese Malays Indians Total p value 
 
    
 Frequency (%) 17499 (85) 2007 (10) 1011 (5) 20517 (100) 
 
 
    
 Age     
 </= 50 (%) 8470 (48) 1203 (60) 464 (46) 10137 (49) <0.005 
>50 (%) 9029 (52) 804 (40) 547 (54) 10380 (51) 
 
 
    
 Stage (% known) 12411 (71) 1389 (69) 730 (72) 14530 (71) 
 
 
    
 Local 7041 (57) 590 (42) 370 (51) 8001 (55) <0.005 
Regional 4431 (36) 584 (42) 303 (42) 5318 (37) 
 Distant 939 (8) 215 (15) 57 (8) 1211 (8) 
 
 
    
 Deaths 6518 (37) 993 (49) 426 (42) 7937 (39) <0.005 
Breast cancer deaths 4736 (27) 795 (40) 311 (31) 5842 (28) <0.005 
            
 
 
Stage distribution over calendar period 
 
Over the calendar years, there is an increase in the proportion of women 
diagnosed with local stage cancer and a corresponding decrease in those with 
regional disease. This trend is consistent across the ethnic groups, with the 
Chinese showing most improvement. Amongst the Malays, the higher proportion 










Overall survival by ethnicity 
 
The overall relative survival for women diagnosed with breast cancer from 1968 
to 2006 appeared better for the Chinese, with the Malays showing the poorest 



































Chinese, Malays and Indians was significantly different at 79%, 59% and 72%, 
respectively (Table 11). 
 
Figure 11 Age standardised relative survival rate by ethnicity and in relation to 
years since diagnosis 
 
 







Characteristic  95% CI   95% CI   95% CI 
2-year survival rates 
        Overall relative survival  90 88 - 92 
 
76 67 - 83 
 
87 76 - 95 
Overall observed 
survival 84 83 - 86 
 
72 64 - 78 
 
82 72 - 89 
               5-year survival rates 
              Overall relative survival  79 76 - 82 
 
59 48 - 68 
 
72 59 - 84 
Overall observed 
survival 66 64 - 68 
 
51 43 - 58 
 
62 52 - 70 
               10-year survival rates 
              Overall relative survival  77 71 - 83 
 
44 31 - 63 
 
63 43 - 87 
Overall observed 
survival 47 45 - 50 
 
32 25 - 41 
 
45 34 - 56 




Survival by ethnicity and stage 
 
When the women were stratified by ethnicity, there was a survival advantage 
seen in the Chinese compared to the Malays. This trend was less consistent 
amongst the Indians (Figure 12). 
 
Figure 12 Five-year relative survival ratios by ethnicity and stage in relation to 
years since diagnosis. 
 
 
Survival by ethnicity, stage and calendar period 
 
Table 12 and Figure 13 show the improved 5-year relative survival rates by 
ethnicity and stage over the calendar period of diagnosis. The Malays with 






Table 12 Five-year relative survival ratios by ethnicity and stage over the 
calendar period of diagnosis 
  
Relative survival rate (CI)   Observed survival rate (CI) 
    1968-1989 
Chinese Local 83 81 - 86 
 
75 73 - 77 
Malays 
 
62 52 - 72 
 
58 48 - 67 
Indians 
 
73 61 - 82 
 
68 57 - 76 
Chinese Regional 50 47 - 53 
 
44 42 - 47 
Malays 
 
35 27 - 43 
 
33 26 - 40 
Indians 
 
45 34 - 57 
 
42 31 - 53 
Chinese Distant 22 17 - 28 
 
19 14 - 24 
Malays 
 
8 3 - 18 
 
8 2 - 17 
Indians 
 
23 6 - 48 
 
21 5 - 45 
   
    1990-2003 
Chinese Local 97 96 - 98 
 
90 89 - 91 
Malays 
 
86 81 - 90 
 
82 77 - 86 
Indians 
 
94 88 - 99 
 
87 81 - 91 
Chinese Regional 76 73 - 78 
 
70 68 - 72 
Malays 
 
64 57 - 69 
 
60 54 - 66 
Indians 
 
72 63 - 79 
 
67 59 - 73 
Chinese Distant 32 27 - 37 
 
28 24 - 33 
Malays 
 
22 14 - 31 
 
20 13 - 29 
Indians 
 
21 9 - 37 
 
20 8 - 36 

















Poisson regression: excess risk of death 
 
Figure 14 presents the risk of death of the women taking age, disease stage, 
period of diagnosis, years of follow-up and ethnicity. As expected, the stage of 
cancer is an important predictor of survival. The risk of death was decreased in 
the later period but the risk of death remained the highest amongst the Malays 








































































5 year Relative survival ratios
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Figure 14 Poisson regression: adjusted excess risk of death by (A) Year of follow 







Table 13 Poisson regression: adjusted excess risk of death stratified by period of 
diagnosis 
  RR 95% CI p-value     RR 95% CI p-value 
 
    
  
    





Year of follow-up 
    
Year of follow-up 
   1 1.0 (reference) 
  
1 1.0 (reference) 
 2 1.1 1.0 1.3 0.162 
 
2 1.3 1.1 1.6 0.001 
3 1.0 0.9 1.2 0.979 
 
3 1.3 1.1 1.6 0.002 
4 0.7 0.6 0.9 0.002 
 
4 1.2 1.0 1.5 0.028 
5 0.7 0.5 0.8 <0.005 
 
5 1.0 0.8 1.3 0.785 
Age group 
     
Age group 
    <35 1.0 (reference) 
  
<35 1.0 (reference) 
 35-54 0.7 0.6 0.8 <0.005 
 
35-54 0.8 0.6 1.0 0.072 
45-54 0.8 0.7 1.0 0.035 
 
45-54 0.7 0.6 0.9 0.013 
55-64 0.9 0.8 1.1 0.49 
 
55-64 0.9 0.7 1.2 0.63 
65-74 0.8 0.6 1.0 0.026 
 
65-74 0.9 0.7 1.2 0.475 
75+ 0.9 0.6 1.3 0.451 
 
75+ 1.0 0.7 1.4 0.94 
Stage 
     
Stage 
    Local 1.0 (reference) 
  
Local 1.0 (reference) 
 
Regional 3.2 2.8 3.7 <0.005 
 
Regio
nal 5.1 4.2 6.0 <0.005 
Distant 9.5 8.0 11.2 <0.005 
 
Distan
t 23.3 19.3 28.2 <0.005 
Ethnicity 
     
Ethnicity 
    
Chinese 1.0 (reference) 
  
Chine
se 1.0 (reference) 
 Malay 1.7 1.5 2.0 <0.005 
 
Malay 1.6 1.3 1.8 <0.005 
Indian 1.1 0.8 1.4 0.623 
 
Indian 1.3 1.1 1.7 0.015 





Methodical considerations  
 
The methodical considerations are similar to study 1 and have been described in 
chapter 3.3. The number of Indian and Malay women was small compared to the 
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Chinese and this has potential sample size bias with decreased predictive 
potential with less than steady trends when associations with various covariates 
were studied.  
 
Effects of Period of diagnosis and Treatment 
 
When compared across the period of diagnosis in the study, there was a 
consistent overall decreased risk of death in all ethnic groups. However, 
treatment information is not available in the study; this is also a limiting factor as 
confounding due to differences in treatment between the groups may impact the 
survival outcome. In addition, women in this study were treated by various 
institutions over a long period of time.  Treatment of breast cancer was 
standardized under institutional practice in Singapore in the 1990s. Variability of 
treatment between institutions over the period could have contributed systematic 
as well as random measurement errors. Nevertheless, comparable survival 
between Singapore and Stockholm (study 1) when the cancer is stratified by 
stage suggest that treatment in Singapore in the later years was comparable and 




Singaporean Malay women were younger and presented in a more advanced 
stage of breast cancer. This was associated with poorer prognosis compared to 
the other ethnic counterparts. Singaporean Chinese had the best prognosis 
compared to the Indians and Malays. This is similar to a recent report using a 
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Singapore-Malaysia hospital based cancer registry for women diagnosed with 
invasive breast cancer from 1995 to 2007(138).  
 
As the Malays fared the poorest even after adjusting for disease stage, age, 
follow up, period of diagnosis, other reasons must be considered.  
 
Tumour biology 
In Asian populations, breast cancers in premenopausal young women were 
associated with higher grade, lymph node involvement and LVI even when 
majority of tumours were ER and PR positive, and associated with a higher 
proportion of cerbB2-positive tumours  compared to SEER data (34). Multiparty 
contributed to a decrease in post-menopausal breast cancer amongst the Malays, 
reducing the median age of women with breast cancer in Malays; this itself could 
have been the reason of higher grade cancers amongst the Malays. In addition, 
earlier age of the first birth and multiparty at a young age possibly contributed to 
the development of tumours with poorer biology of higher grade and presence of 
LVI.  
 
However, differences in tumour biology and characteristics were not available for 
comparison as a probable cause for the differences seen in this study. Similar to 
study 1, this is again a limiting factor as confounding because differences in 





Socioeconomic status and cultural differences 
Malays in Singapore tended to have poorer SES (Chapter 1) and this is also 
associated with lower education and together, these could affect their awareness 
and understanding of the disease, seeking of medical attention and their choice 
of accepting recommended treatment. This is also supported by the higher 
proportion of advanced stage cancer in this study, likely synonymous with delay 
in seeking treatment. Cultural and religious beliefs affect relationships with men, 
perceived risk, and beliefs in traditional or alternative treatments for breast 
cancer, may affect disease awareness, access to early detection and thus stage 
at presentation of breast cancer and treatment (70). Cultural differences in coping 
mechanisms that our women have when faced with the fear of being diagnosed 
with breast cancer, may affect their attitude to the disease, and hence delay 
diagnosis and treatment. 
  
Several studies from our neighbouring Malaysia showed that fear of surgery, 
influence by friends, belief that alternative therapy works, bad experience in 
hospital, financial problems, fear of inability to work after the mastectomy, lack of 
time, having young children, believing that prayer was sufficient, were reasons for 
delaying medical attention and treatment, and choosing alternative therapy; this 
was especially prevalent amongst the Malays (139; 140). A report in 2007 
studying women who present with late disease revealed that a fatalistic view of 
cancer may be a reason for women not wanting to have treatment (141). Use of 
alternative therapy was another observation in this group, which included oral 
preparations, applications and spiritual prayers. Similarly, psychosocial factors 
due to the similar cultural and religious beliefs in each of the ethnic groups in 




Other factors such as BMI, diet, and other behavioural, or environmental 
differences are not available in this study. But Singapore have few women who 
smoke 3.2% (2004 National Health Survey statistics)  (127). Only about 6% of 
postmenopausal women in Singapore are on hormonal replacement therapy for 
menopause (128); Chinese women have a high intake of soy and consume the 
lowest amount of dietary fat (74) while Malay women are less likely to consume 
alcohol. Prevalence of obesity (BMI>/=30kg/m2) is highest  in Malay women 
(23.1%), compared to the Chinese (3%) and Indians (18.3%) as reported in the 




Trends in breast cancer survival between ethnic groups in Singapore: Chinese, 
Malays and Indians were different. There were more premenopausal Malays 
presenting with breast cancer compared to the Chinese and Indians. They 
presented with a more advanced stage of disease and have poorer prognosis 
even after adjusting for disease stage, age, follow up, period of diagnosis. 
Tumour biology and treatment information is not available in this study, but 
perhaps socioeconomic status, cultural and lifestyle differences between the 
ethnic groups could explain some of the survival difference. The effect of tumour 




CHAPTER 5 Study 3: Effect of Tumour Biology on the 
Survival of Breast cancer amongst different ethnic groups 
in Singapore: an institutional study   
 
5.1 Subjects and Methods  
 
Singapore Hospital Based Cancer Registry 
The Singapore General Hospital-National Cancer Centre Breast Tumour Board 
(BTB) was started in 2001. It collects prospectively voluntary reports of patients 
diagnosed and treated for breast cancer mainly in the Department of General 
Surgery, Singapore General Hospital and Department of Surgical Oncology, 
National Cancer Centre, Singapore. The database records almost 700 new 
breast cancers a year, and consists of breast surgeons, medical and radiation 
oncologists, and pathologists. This is convened weekly to review all cases 
treated. Patient demographics, history of cancer, cancer histology and 
characteristic, staging details, surgery and neoadjuvant treatment details are 
recorded in a computer database, maintained by an informatics team.  Adjuvant 
treatment recommendations made at the meeting are also recorded. The 
completeness of reporting is not known but it has been expected to improve over 
the years. Patients less likely to be recorded would include those who were not 
seen by the two surgical departments and did not have surgical treatment.  
 
A total of 2245 Chinese, Malay and Indian female Singaporean residents with 
unilateral primary invasive breast carcinoma recorded from 2001 to 2007 in the 
BTB were included. Women with a previous malignancy, including contralateral 
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breast cancer were excluded from the study. Follow-up to 31 December 2010 
with death information was obtained by matching with the national death register 
and case note reviews. The methods were similar to study 1 and 2, and have 
been described in 3.1. 
 
The clinical stage was determined from the tumour, lymph node involvement and 
metastatic disease at diagnosis and classified as local, regional and distant 
(metastasis). Classifications into clinical subtypes were done according to the ER, 
PR and cerbB2/HER2 status on IHC and or FISH (Table 14): 
 










   
HER2- 
either or both (+) 
(-) 
HER2+ (+) 
Triple negative (-) (-) (-) 
HER2 positive (-) (-) (+) 






Table 15 shows the characteristics of the Singaporean Chinese, Malay and 
Indian women treated for breast cancer in a local institution for breast cancer 
from 2001 to 2007, with follow up till 31 December 2010. The ethnic distribution is 
comparable to the population study (study 2); similarly, the Malays were younger 
and presented in more advanced stage compared to the Chinese and Indians. 
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Staging is based on histopathology except for 7% of cases with neoadjuvant 
chemotherapy and 4% with metastatic disease. The all cause and breast cancer 
death was highest amongst the Malays during the follow-up period.  
Eighty-three per cent received complete loco regional surgery, with either a 
mastectomy or breast conservation; and axillary surgery. Two per cent did not 
have any operation while just 9 women had either excision of the tumour only or 
axillary clearance only (others). Eight per cent received chemotherapy as 1st line 
treatment, of which 97% were neoadjuvant chemotherapy; the rest were palliative 
in nature. Detailed information on adjuvant therapy such as chemotherapy, 
hormonal therapy, targeted therapy (Herceptin) and radiotherapy were not 
available in the database, but were available as Tumour Board recommendations, 




Table 15 Characteristics and treatment of Singaporean women with breast 
cancer by ethnicity 
Characteristic (%) Chinese Malays Indians Total p 
      Frequency  1940 (86) 192 (9) 113 (5) 2245 (100) 
 
      Age 
     </= 50  753 (39) 105 (55) 54 (48) 912 (41) < 0.005 
>50  1187 (61) 87 (45) 59 (52) 1333 (59) 
 
      
Stage* (% complete) 1925 (99) 191 (99) 
113 
(100) 2229 (99) < 0.005 
Local 1085 (56) 73 (38) 58 (51) 1216 (55) 
 Regional 768 (40) 101 (53) 51 (45) 920 (41) 
 Distant 72 (4) 17 (9) 4 (4) 93 (4) 
 
      Deaths 324 (17) 54 (28) 21 (19) 399 (18) < 0.005 
Breast cancer deaths 283 (15) 48 (25) 19 (17) 350 (16) 
             
Treatment modality 
     Breast and axillary surgery 
     Local and regional disease (n=2136) 
    Complete surgery**  1817 (98) 171 (98) 105 (86) 2093 (98) 0.169 
Incomplete surgery 27 (1) 1 (0.6) 4 (4) 32 (92) 
 None 9 (0.5) 2 (1) 0 11 (0.5) 
 
      Metastatic or incomplete staging (n=109) 
    Complete surgery**  53 (61) 14 (78) 4 (100) 71 (65) 0.228 
Incomplete surgery 6 (7) 2 (14) 0 8 (65) 
 None 28 (32) 2 (11) 0 30 (28) 
 
      Type of breast surgery (n=2245) 
     None 37 (1.9) 4 (2.1) 0 41 (1.8) 0.828 
Mastectomy 1357 (69.9) 
131 
(68.2) 78 (69) 1566 (69.8) 
 
Breast conservation 539 (27.8) 56 (29.2) 
34 
(30.1) 629 (28) 
 Others 7 (0.4) 1 (0.5) 1 (0.9) 9 (0.4) 
 
      Neoadjuvant chemotherapy 
(n=2136) 123 (7) 21 (12) 9 (8) 153 (7) 0.444 
            
*Staging is based on histopathology except for 7% of cases with neoadjuvant chemotherapy and 4% with metastatic 
disease  
** Complete surgery refers to complete breast and axillary surgery; incomplete surgery refers to either breast surgery 







Characteristics by ethnicity 
The differences in tumour histopathological characteristics by ethnicity are 
described in Table 16. The proportions of ER, PR and HER2 status of tumours 
are similar across the ethnic groups; but Chinese have fewer grade 3 tumours 
and tumours which are less likely to have lymphovascular invasion. When the 
tumours were classified into subtypes based on the receptor status, there 
appears to be more triple negative tumours amongst the Indians (p=0.298).  
 
Within each ethnic group, there was no significant change in ER and PR positivity 
and LVI  by age groups; but in the Chinese, proportion of grade 3 tumours 
decreased with increasing age (p=0.042), this trend was also present in the 
Malays, though not significant (p=0.234),  while the numbers were too small 
amongst the Indians. ER positivity was similar across age groups by ethnicity 
Figure 15. 
 
Table 17 and Table 18 show the correlation between LVI and grade with the 
receptor status and clinical subtypes, where ER and PR negative tumours are 
more likely high grade; HER2 positive tumours are more likely LVI positive.  
 
Characteristics by tumour subtype 
Table 18 demonstrates association of the clinico-pathologic variables with the 
clinical tumour subtypes. Although the duration of study is short, there was a shift 
in the later 3 years towards more ER/PR+ tumours compared to the initial 4 years.    
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Table 16 Tumour characteristics by ethnicity 
Characteristic (%) Chinese Malays Indians Total p 
      Receptor status  
     ER (% available) 1910 (98) 192 (100) 111 (98) 2213 (99) 
 Positive 1300 (68) 127 (66) 70 (63) 1497 (68) 0.493 
Negative 610 (32) 65 (34)  41 (37) 716 (32) 
 
      PR (% available) 1901 (98) 191 (99) 111 (98) 2203 (98) 
 Positive 1108 (58) 110 (58) 66 (59) 1284 (58) 0.951 
Negative 793 (48) 81 (42) 45 (41) 919 (42) 
 
      HER2 (% available) 1624 (84) 167 (87) 100 (88) 1891 (84) 
 Positive 390 (24) 47 (28) 20 (20) 457 (24) 0.3 
Negative 1234 (76) 120 (72) 80 (80) 1434 (76) 
             
Grade of tumour (% available) 1837 (95) 187 (97) 109 (96) 2133 (95) 
 1 329 (18) 27 (14) 12 (11) 368 (17) 0.015 
2 701 (38) 57 (30) 40 (37) 798 (37) 
 3 807 (44) 103 (55) 57 (52) 967 (45) 
 
      LVI (% available) 1695 (87) 170 (89) 100 (58) 1965 (88) 
 No 1205 (71) 102 (60) 65 (65) 1372 (80) 0.006 
Yes 412 (29) 59 (40) 27 (35) 498 (30) 
 
      Subtype classification  
     
      Frequency (% available) 1604 (83) 165 (86) 100 (88) 1869 (83) 0.298 
ER/PR positive 1162 (72) 120 (73) 68 (68) 1350 (72) 
 HER2- 959 (60) 92 (56) 56 (56) 1107 (59) 
 HER2+ 203 (12) 28 (17) 12 (12) 243 (13) 
 
      Triple negative 258 (16) 26 (16) 24 (24) 308 (16) 
 
      HER2 positive 184 (11) 19 (12) 8 (8) 211 (11) 
 (ER/PR-, HER2+)           
ER/PR positivity is based on 10% or more of invasive tumour cells staining with an intensity of at least 2+.HER2 positivity 
is based on cerbB2 by IHC: 65% had raw scores of intensity of 3+, 35% were recorded as positive without details of raw 




Table 17 Tumour characteristics by receptor status 
  ER PR HER2 
Tumour characteristics Positive Negative Positive Negative Positive Negative 
Grade 
      1 346 (24) 18 (3) 293 (24) 71 (8) 16 (4) 303 (22) 
2 638 (45) 151 (22) 529 (43) 256 (29) 146 (33) 544 (39) 








      Positive 386 (29) 200 (32) 332 (29) 252 (31) 146 (37) 345 (27) 







               
 
 















      Age 
     
0.085 
< or = 50 473 (42) 105 (43) 110 (35) 78 (37) 766 (41) 
 50+ 641 (58) 140 (57) 200 (65) 133 (63) 1114 (59) 
 
       Period 
      2001-2004 552 (55) 148 (15) 187 (18) 125 (12) 1012 (100) < 0.005 
2005-2007 562 (65) 97 (11) 123 (14) 86 (10) 868 (100) 
 
       Stage 
     
0.001 
Local 641 (58) 122 (50) 166 (54) 90 (43) 1019 (54) 
 Regional 431 (39) 111 (45) 123 (40) 105 (50) 770 (41) 
 Distant 35 (3) 10 (4) 19 (6) 16 (8) 80 (4) 
 Incomplete 7 (1) 2 (1) 2 (1) 0 (0) 11 (1) 
 
       Grade 
     
< 0.005 
1 292 (27) 15 (6) 10 (3) 1 (1) 318 (18) 
 2 485 (45) 89 (37) 54 (18) 56 (28) 684 (38) 
 3 300 (28) 134 (56) 232 (78) 141 (71) 807 (45) 
 
       LVI 
     
0.001 
No 735 (66) 134 (55) 192 (62) 110 (52) 1171 (62) 
 Yes 266 (24) 73 (30) 75 (24) 73 (35) 487 (26) 
 Not available 113 (10) 38 (16) 43 (14) 28 (13) 222 (12) 
   




Overall survival by ethnicity 
The overall survival is similar to the population study in study 2, where the 
Chinese constantly outperformed the Malays and the Indians. The overall age-
standardized 5-year relative survival for the Chinese, Malay and Indian women 
was significantly different at 83%, 64% and 72% respectively (Figure 16 and 
Table 19). The trend is less stable in the Indians due to the small population size.  
 
Figure 16 Overall 5-year age-standardized relative survival of women with breast 







Table 19 Overall and stage specific 5-year age-standardised relative survival of 
Singaporean women 
Characteristic Chinese   Malays   Indians 
Overall 5-year survival rates % 95% CI 
 
% 95% CI 
 
% 95% CI 
Overall observed survival 97 88 - 103 
 
72 45 - 97 
 
76 65 - 80 
Overall relative survival  83 77 - 87 
 
64 42 - 83 
 
72 61 - 76 
               Specific 5-year relative survival 
             Local 108 98 - 113 
 
79 59 - 85 
 
80 73 - 83 
Regional 89 73 - 100 
 
71 32 - 100 
 
74 52 - 81 
Distant  37 15 - 57 
 
18 1 - 42 
 
15 15 - 15 
                              
 
 
Survival by ethnicity and stage 
The survival trend by ethnicity and stage in this institutional cohort is consistent 
with the Singapore population in study 2, but the trend is less stable as the 
number of Malay and Indian women in this study cohort is small (Figure 17). The 
5-year RSR amongst the Chinese women with localised cancer was 108%. A 
relative survival greater than 100% indicates better survival among the Chinese 
women with localized breast cancer than in the general population. This is 
usually observed when statistics are based on small numbers of cases, unlikely 
in this study; or competing mortality is lower in these women as compared with 
the general population. This may be due selection bias of Chinese women with 
lower comorbidity with tumours that are indolent, nonlethal and do not limit their 
survival. This may also be due to a ‘healthy patient effect’, whereby these 
patients experience lower mortality due to other causes as a result of having 
greater than average contact with the health system, change in lifestyle and 




This was also seen in a study where a relative survival >100% was seen in men 
with low-grade prostate cancer, regardless of treatment, at least during the first 5 
years. This paradoxically high relative survival rate is probably explained by a 
selection of men with lower comorbidity and tumours that do not limit the survival 
of their hosts, in whom tumours are revealed despite few or minor symptoms. 
Men with similar tumours but more concurrent disease are less likely to undergo 
an examination in which indolent, nonlethal tumours would be detected. 
Consequently, men with low-grade prostate cancer appear to have better survival 
than the general population (142). 
 
Figure 17 Five-year age-standardized relative survival of women with breast 
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Survival by tumour subtypes 
Overall prognosis by subtype classification based on tumour receptor: ER, PR 
and HER2 in Figure 18 showed that women with ER and/or PR positive tumours 
have similar survival, but those whose tumours were ER/PR positive, HER2 
negative performed better compared to those who were ER/PR positive, positive. 
Those with triple negative (ER/PR/HER2-) and ER/PR-, HER2+ tumours fared 
poorer and the survival was similar in these 2 groups (p<0.05).    
 
Figure 18 Five-year age-standardized relative survival of women with breast 
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Survival by ethnicity and tumour subtypes 
 
Figure 19 shows the 5-year age-standardised relative survival by ethnicity and 
subtype. As the numbers amongst the Malays and Indians were small, the 
subtype classification was regrouped into 2 groups:  ER/PR+ (ER+ and/or PR+, 
HER2- and  ER+ and/or PR+, HER2+) and ER/PR- (ER-, PR-, HER2- and ER-, 
PR-, HER2+). The number of events was still too few amongst the Indians to 
show any discernible estimates.  
 








C: Chinese, M: Malays, I: Indians; ER/PR+ (ER+ and/or PR+, HER2- and  ER+ and/or PR+, HER2+) 
and ER/PR- (ER-, PR-, HER2- and ER-, PR-, HER2+); RR: relative risk of mortality by ER/PR- to 
ER/PR+ status within each ethnic group; unadjusted. 
  
Ethnicity RR 95% CI p 
Chinese 4.3 2.6 7.2 <0.005 























Years since diagnosis 










Poisson regression: excess risk of death 
 
Table 20 presents the risk of death of the women by ethnicity, disease stage, 
tumour subtype, tumour grade, LVI with years of follow-up taken into account. 
The survival for ER/PR+/HER2+ and ER/PR+/HER2- were similar and hence 
were grouped as ER/PR+ in the univariate and multivariate analysis because of 
the small numbers of Malay and Indian women in the study. Age was not a 
significant factor. On multivariate analysis, as expected, the stage of cancer is an 
important predictor of survival. Malay women have twice the risk of death 
compared to the Chinese women. Tumour characteristics: tumour subtype, grade 
and LVI independently predicted prognosis.  
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Table 20 Poisson regression analysis: univariate and multivariate analysis 
Variable HR p 95% CI   Variable HR p 95% CI 
Univariate*         
 
Multivariate         
Clinical 
     
Clinical 
    Ethnicity 
     
Year of follow up 
    Chinese 1.0 (reference) 
  
1 1.0 (reference) 
 
Malay  2.5 <0.005 1.6 6.3 
 
2 2.2 0.011 1.2 4.0 
Indian 0.9 0.891 0.3 2.5 
 
3 2.4 0.004 1.3 4.4 
      
4 1.8 0.083 0.9 3.5 
Age 
     
5 2.2 0.027 1.1 4.3 
</= 50 1.0 (reference) 
   
    
>50 0.9 0.461 0.6 1.3 
 
Ethnicity 
    
      
Chinese 1.0 (reference) 
 
Stage 
     
Malay  1.7 0.023 1.1 2.7 
Local & Regional 1.0 (reference) 
  
Indian 0.7 0.488 0.3 1.8 
Distant 12.3 <0.005 7.9 19.1 
  
    
      
Stage 
    
Tumour 
     
Local & Regional 1.0 (reference) 
 
Subtype 
     
Distant 6.9 <0.005 3.5 13.6 
ER/PR positive 1.0 (reference) 
   
    
Triple negative 4.4 <0.005 2.7 7.0 
 
Tumour 
    
HER2 positive 3.5 <0.005 2.0 6.0 
 
Subtype 
    
      
ER/PR positive 1.0 (reference) 
 
Grade 
     
Triple negative 3.4 <0.005 2.2 5.3 
1 and 2 1.0 (reference) 
  
HER2 positive 2.1 0.003 1.3 3.4 
3 1.6 <0.005 1.0 2.2 
  
    
      
Grade 
    
LVI 
     
1 and 2 1.0 (reference) 
 
Yes 1.0 (reference) 
  
3 1.7 0.028 1.1 2.6 
No 0.2 <0.005 0.1 0.3 
  
    
      
LVI 
    
      
Yes 1.0 (reference) 
 
      
No 0.4 <0.005 0.3 0.6 
*Adjusted for years of follow up 







This is a single institution based study and has limitations related to selection 
bias, being a single tertiary centre which may treat patients with different medical 
attention seeking behaviour and treatment preferences; completeness of the 
database; as well as sample size. However, being the largest institution in 
Singapore, it still recorded a large number of cases, treating about 700 cases of 
breast cancer a year. The clinic-pathological information in the database enabled 
the study of factors otherwise not available in the population database. 
 
Malays and Indians form a small proportion of the study population and the ability 
to analyse the different subgroups by age, subtype, stage, grade and LVI is 
limited especially amongst the Indians. Women with distant metastatic disease in 
this database were likely under reported; as compared with the population study 
(study 4), however, the proportion of those with distant disease is small even at 
the population level of about 8% compared to 4% in this series. Although this is 
not reflective of the distribution in the general population, the aim of this study 
was to study the effects of the receptor status of the tumours between the ethnic 
groups; the contribution of the difference in distribution may not have a significant 
consequence. However, it does limit the ability to assess differences in women 
with metastatic breast cancer especially amongst the Malays and Indians where 




A relative survival greater than 100% indicates better survival among the Chinese 
women with localized breast cancer than in the general population. This may be 
observed when statistics are based on small numbers of cases, unlikely in this 
study; or competing mortality is lower in these women as compared with the 
general population. This may be due selection bias of Chinese women with lower 
comorbidity with tumours that are indolent, nonlethal and do not limit their 
survival. This may also be due to a ‘healthy patient effect’, whereby these 
patients experience lower mortality due to other causes as a result of having 
greater than average contact with the health system, change in lifestyle and 
health habits after breast cancer diagnosis which alters death rates from other 
diseases. 
 
This is similar to a study where a relative survival >100% was seen in men with 
low-grade prostate cancer, regardless of treatment, at least during the first 5 
years. This paradoxically high relative survival rate is probably explained by a 
selection of men with lower comorbidity and tumours that do not limit the survival 
of their hosts, in whom tumours are revealed despite few or minor symptoms. 
Men with similar tumours but more concurrent disease are less likely to undergo 
an examination in which indolent, nonlethal tumours would be detected. 
Consequently, men with low-grade prostate cancer appear to have better survival 
than the general population (142). 
 
The completeness of tests on tumour characteristics such as receptor status, 
LVI and grade were not available in 5 to 17% of the cases in the study. This was 
inevitable as some of these tumours were too small to assess these parameters 
or the IHC tests failed on the sample. Study of these early cancers in relation to 
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their receptor status would be diminished, but fortunately these did not contribute 
a large number.  
 
Exclusion of unknown cases e.g., on the HER2 may introduce bias for complete 
case analysis in a review by Bhoo PN et al (143). However, in this reference, 
there was a selection bias of when HER2 status was assessed: in the group of 
patients where the lowest predicted mortality risk and patients with highest 
predicted mortality risk were significantly less likely to be tested for HER2 status, 
whereas those with intermediate predicted mortality risk were more likely to be 
tested.  
 
In our series, all cases were assessed for cerbB2, with no selection based on 
expected mortality or on other clinical parameters. The cases where complete 
receptor status, i.e., all 3: ER, PR and cerbB2 were not available for the 
subtyping and were grouped as unknown were mainly due to the indeterminate 
or unknown HER2 status, where the cerbB2 was 2+/equivoval/indeterminate 
(74%), while the rest were either not assessable because of a small invasive 
focus, in post-neoadjuvant cases or not done. As use of Herceptin as adjuvant 
therapy was not yet standard therapy, HER2 by FISH was not performed. This by 
itself would introduce a similar selection bias as referenced, but perhaps to a 
lesser degree as more than 80% of the tumours had known HER2 status, either 
positive or negative.  
 
In this study, the relative survival for the unknown group was very similar to the 
ER+/PR+/HER2- group i.e., of good prognosis and account for about 16% of all 
the cases, of which two thirds were ER/PR positive. When these cases were 
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reviewed and compared against the various parameters, they were comparable 
by stage, ethnicity and age, hence in risk stratification against these variables, 
the bias if present is unlikely significant. 
 
Histology and immunohistochemistry was used to assess the tumour and tumour 
receptor status. Like grade and LVI, these variables are subject to measurement 
bias as there are inter-observer as well as inter-assay variability; However, as a 
large tertiary centre with a high clinical load and experienced pathologists; as well 
as that the laboratories receive rigorous assessment and accreditation from the 
College of American Pathologists (CAP) and follow the American Society of 
Clinical Oncology/College of American Pathologists guidelines of sample 
handling, this possible systematic observer bias resulting in misclassification is 
likely reduced. The cut-off for determining positivity of receptor status has 
changed over the years, but for the duration of the study, there was no change 
within our laboratory; a semi-quantitative method defined ER positivity as 10% or 




The proportion of ER positive tumours are higher in this study when compared to 
previous reports (144; 145). This could be due to the selection criteria differences; 
this study comprised only of women with no prior or bilateral breast cancer. Prior 
or bilateral breast cancer has been associated with higher ER positive tumours. 
Treatment with anti-oestrogen in patients with ER-positive tumours decreased 
the risk of second ER-positive tumours but not ER-negative tumours (146). The 
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risk of second ER-negative breast cancer is very high after a first ER-negative 
tumour, in particular among women with strong family history (147). In addition, 
ER negativity as a risk factor for developing metachronous tumours (148) with 
ER-negative first cancer have a specifically increased risk of ER-negative 
contralateral breast cancer (149). While there was no significant difference in 
survival for patients with bilateral compared to unilateral tumour, synchronous 
tumour has been associated with poorer survival in comparison to metachronous 
tumour (150). 
 
Overall, a shift towards more ER-positive disease was found during the latter part 
of the study period; this could reflect screening practices as our national breast 
screening program started in 2002, but this could still influence survival (151), as 
also seen in study 2.  
 
The ER and PR status and clinical subtype was similar between the ethnic 
groups suggesting that the proportion of ER and PR status was not affected or 
not in the same manner by ethnicity or ethnic related factors between them. 
Chinese with ER/PR positive tumours showed better survival compared to those 
with ER/PR negative tumours, the unadjusted relative risk of 4.3, p<0.005, while 
the relative risk was 2.4, p=0.056 amongst the Malays; the numbers were too 
small amongst the Indians. The HER2 receptor positivity was more common 
amongst the Malays although this was not statistically significant. Similar to the 
African American, when the tumours were classified into subtypes based on the 
receptor status, Indians too seem to have a higher proportion of triple negative 
cancers (52) though not statistically significant, and this had been associated with 




The Chinese have the better tumour characteristics such as lower grade and LVI 
negative tumours explaining the better prognosis, while high grade tumours and 
tumours with LVI was seen in larger proportions in the Malays and Indians 
contributing to the poorer survival amongst the Malays. Consistent with known 
reports on tumour biology (152), correlation between LVI and grade with the 
receptor status, where ER and PR negative, and HER2 positive tumours are 
more likely high grade; HER2 positive tumours are more likely LVI positive were 
also seen in the study.  
 
Hence, receptor status is not responsible for the poorer survival in Malays; grade 
and LVI were likely reasons for the survival difference. However, ethnicity is still a 
significant risk of death where Malays have twice the risk of death in Chinese 
after adjusting for disease stage, tumour subtype, tumour grade, LVI and years of 
follow-up. Either genetic difference that are not seen by the ER, PR or HER2 
phenotype affect the prognosis, or other factors such as psychosocial factors 
associated with ethnicity contribute to the survival difference as discussed in 




It is interesting to find that ER status was comparable between the Chinese, 
Malays and Indians, as well as by menopausal status (using age 50 years old as 
the cut-off); similarly for PR and HER2 status resulting in similar clinical subtypes 
distribution between the ethnic groups. Women with different tumour subtypes 
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showed different survival amongst the Chinese, but this was not significant 
amongst the Malays. Although tumour grade and LVI were correlated with 
ethnicity, they were independent predictors of risk of death. Ethnicity was also an 
independent risk of death; hence, tumour biology alone does not explain the 
difference in survival difference between ethnicity.     
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CHAPTER 6 STUDY 4: CUSTOM MULTI-SIGNATURE 
ARRAY (MSA) FOR BREAST CANCER IN SINGAPORE 
 
6.1 Subjects and Methods  
 
Tissue Repository 
In study 4, human breast tissues from the period 2000-2004 were obtained from 
the National Cancer Centre (NCC) Tissue Repository, after appropriate approvals 
from the National Cancer Centre Repository and Ethics Committees and the 
Singapore General Hospital Ethics Committee. Samples were selected using the 
following predefined inclusion criteria: histological diagnosis of invasive ductal 
carcinoma (IDC) of the breast, newly diagnosed non-metastatic breast cancer 
with no prior treatment, no history of other cancers or the presence of 
synchronous contra-lateral breast cancer, availability of frozen tissue and 
complete clinical data. Exclusion criteria were: tumours with no detectable IDC on 
haematoxylin and eosin (H&E) sections of the frozen sample, and degraded RNA. 
All patients underwent surgical treatment, mastectomy or breast conservation 
surgery, and were given adjuvant therapy: chemotherapy, hormonal therapy and 
chest wall radiotherapy according to institutional practice guidelines. Tissue 
harvesting, preparation for storage, storage and release of tissue was performed 
by the NCC Tissue Repository and under Repository Protocols. Follow-up was 
done by matching with the national death register for all studies, as well as 





Clinical and histopathology variables 
Clinical variables age, ethnicity and histological variables including tumour size, 
nodal status, tumour subtype, histologic grade (modified Bloom-Richardson 
grading), lymphovascular invasion (LVI), and ER, PR and HER2 status were 
collected from the formal histological report.  
Repeat assessment by immunohistochemistry (IHC) were done for study 4 by 
two pathologists. Immunohistochemistry antibodies were SP1 for ER and SP3 for 
HER2 (Labvision); ER/PR positivity is 10% or more of invasive tumour cells 
staining with an intensity of at least 2+. HER2 IHC staining scored according to 
Herceptest specifications (DAKO). HER2 positivity was based on FISH, which 
was done on all the frozen tissue samples using the PathVysion kit from Vysis, 
Inc., in which a HER2/CEP ratio of 2.2 was deemed as amplified according to the 
2007 American Society of Clinical Oncology/College of American Pathologists 
guidelines (84). Immunohistochemistry and FISH were done in the Department of 
Pathology, Singapore General Hospital, a College of American Pathologists 
accredited laboratory. Concordance between HER2 FISH and 
immunohistochemistry obtained by our laboratory reported 100% for 
immunohistochemistry 3+ and 85% for immunohistochemistry 2+ in the recent 
review of consecutive routine cases of invasive breast cancer done on paraffin 
sections. This percentage is well within the variables recommended for HER2 
testing by Wolff et al. (84). FISH is not routinely done for immunohistochemistry 




Multiple signature assay (MSA) 
 
MSA Chip Design 
The breast cancer MSA was fabricated using CombimatrixTM electrochemical in-
situ synthesis technology, and contains probes for 188 genes representing five 
previously identified breast cancer molecular signatures. These include 
signatures for the Luminal/ER+, HER2, and basaloid subtypes of breast cancer, 
which we had previously shown to be present in the Asian breast cancer 
population (95; 105); and 2 expression signatures previously identified by the 
research group in NCC using local breast cancer tumours: NPI-ES, a molecular 
signature of the Nottingham Prognostic Index, a pathologic stratification staging 
system for breast cancer prognostication(96); and TuM1, a signature for low 
histologic grade that may also serve as a potential predictive biomarker for 
tamoxifen response(153). Notably, both the NPI-ES and TuM1 signatures are 
specific to Luminal/ER+ tumours. A complete list of MSA genes is provided in   
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Table 21. For each gene, we used vendor-provided software to design five 
independent (35mer) probes, and each probe was replicated eight times across 
the MSA at random locations. We also included forty-five control genes from 
different cellular pathways as internal standards for normalizing RNA expression 
levels (38). Finally, 25mer sequences (5 replicates per probe) designed against 
the 20x Eukaryotic Hybridization Control Kit (Affymetrix) was included to facilitate 





Table 21 List of genes on the MSA.  a) Luminal/Oestrogen Receptor positive 
(ER+), b) HER2, and c) ‘Basaloid’, d) Nottingham Prognostic Index (NPI-ES), and 
e) low histologic grade (TuM1). 
 
GenBank ID                                                          Gene Name 
a) Luminal/Oestrogen Receptor (ER+) 
NM_005080 X-box binding protein 1 
NM_004374 cytochrome c oxidase subunit Vic 
AL572542 CGI-49 protein 
AI635449 solute carrier family 39 (zinc transporter), member 6 
NM_021173 polymerase (DNA-directed), delta 4 
NM_004636 
sema domain, immunoglobulin domain (Ig), short basic domain, secreted, 
(semaphorin) 3B 
AI435828 stanniocalcin 2 
H05812 insulin-like growth factor 1 receptor 
NM_000633 B-cell CLL/lymphoma 2 
NM_001218 carbonic anhydrase XII 
AI857639 phorbol-12-myristate-13-acetate-induced protein 1 
BC001012 carbonic anhydrase XII 
NM_005375 v-myb myeloblastosis viral oncogene homolog (avian) 
NM_003225 trefoil factor 1 (breast cancer, estrogen-inducible sequence expressed in) 
NM_003462 dynein, axonemal, light intermediate polypeptide 1 
NM_000125 estrogen receptor 1 
NM_000156 guanidinoacetate N-methyltransferase 
NM_014668 GREB1 protein 
NM_003834 regulator of G-protein signalling 11 
J03778 microtubule-associated protein tau 
NM_000767 cytochrome P450, family 2, subfamily B, polypeptide 6 
NM_002570 proprotein convertase subtilisin/kexin type 6 
J02639 
serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), 
member 5 
AF237813 4-aminobutyrate aminotransferase 
BC003070 GATA binding protein 3 
AF230929 annexin A9 
M29873 cytochrome P450, family 2, subfamily B, polypeptide 6 
BC002915 discs, large homolog 5 (Drosophila) 
AB015706 interleukin 6 signal transducer (gp130, oncostatin M receptor) 
AK023837 thyroid hormone receptor associated protein 2 
BE256900 jumonji domain containing 2B 
BF131791 WW domain containing E3 ubiquitin protein ligase 1 
AI348094 KIAA0882 protein 
BF508639 elongation of very long chain fatty acids (FEN1/Elo2, SUR4/Elo3, yeast)-like 2 
L48722 protein tyrosine phosphatase type IVA, member 2 
NM_014019 HSPC009 protein 
NM_018478 chromosome 20 open reading frame 35 
NM_024573 chromosome 6 open reading frame 211 
NM_022131 calsyntenin 2 
AI378044 UDP-glucose ceramide glucosyltransferase 
BC000580 hypoxia-inducible factor prolyl 4-hydroxylase 
AK001105 LAG1 longevity assurance homolog 2 (S. cerevisiae) 
D87469 cadherin, EGF LAG seven-pass G-type receptor 2 (flamingo homolog, Drosophila) 
100 
 
NM_005264 GDNF family receptor alpha 1 
 
b) HER2 
NM_000126 electron-transfer-flavoprotein, alpha polypeptide (glutaric aciduria II) 
NM_021122 acyl-CoA synthetase long-chain family member 1 
NM_002964 S100 calcium binding protein A8 (calgranulin A) 
NM_006804 START domain containing 3 
NM_003064 secretory leukocyte protease inhibitor (antileukoproteinase) 
AI758763 transducin-like enhancer of split 1 (E(sp1) homolog, Drosophila) 
NM_002965 S100 calcium binding protein A9 (calgranulin B) 
NM_005923 mitogen-activated protein kinase kinase kinase 5 
AW157202 SRY (sex determining region Y)-box 11 
NM_014817 KIAA0644 gene product 
NM_006741 protein phosphatase 1, regulatory (inhibitor) subunit 1A 
NM_014274 transient receptor potential cation channel, subfamily V, member 6 
BC005047 dual specificity phosphatase 6 
AF289489 aspartate beta-hydroxylase 
AB008790 growth factor receptor-bound protein 7 
BC005297 kynurenine 3-monooxygenase (kynurenine 3-hydroxylase) 
AF202063 fibroblast growth factor receptor 4 
AB029025 KIAA1102 protein 
NM_003221 transcription factor AP-2 beta (activating enhancer binding protein 2 beta) 
X03363 
v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma 
derived oncogene homolog (avian) 
BF003134 chloride channel, calcium activated, family member 2 
BF589529 DBCCR1-like 
NM_024306 fatty acid 2-hydroxylase 
NM_024861 hypothetical protein FLJ22671 




keratin 5 (epidermolysis bullosa simplex, Dowling-Meara/Kobner/Weber-Cockayne 
types) 
NM_005228 
epidermal growth factor receptor (erythroblastic leukemia viral (v-erb-b) oncogene 
homolog, avian) 
NM_015271 tripartite motif-containing 2 
NM_001444 atty acid binding protein 5 (psoriasis-associated)  
NM_012101 tripartite motif-containing 29 
NM_002423 matrix metalloproteinase 7 (matrilysin, uterine) 
NM_004949 desmocollin 2 
NM_002639 serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 5 
NM_014211 gamma-aminobutyric acid (GABA) A receptor, pi 
NM_006533 melanoma inhibitory activity 
NM_030920 
acidic (leucine-rich) nuclear phosphoprotein 32 family, member E /// acidic (leucine-
rich) nuclear  
phosphoprotein 32 family, member E 
AF007162 crystallin, alpha B 
AF061812 keratin 16 (focal non-epidermolytic palmoplantar keratoderma) 
AI367319 SRY (sex determining region Y)-box 10 
AK026420 Desmuslin 
AU145890 forkhead box C1 
AI831452 keratin 6B 
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BE542323 vestigial like 1 (Drosophila) 
NM_022893 B-cell CLL/lymphoma 11A (zinc finger protein) 
NM_003740 potassium channel, subfamily K, member 5 
NM_007231 solute carrier family 6 (neurotransmitter transporter), member 14 
NM_017422 calmodulin-like skin protein 
NM_017578 ropporin, rhophilin associated protein 1 
NM_001426 engrailed homolog 1 
Z19574 keratin 17 
 
d) Nottingham Prognostic Index (NPI-ES) 
NM_002106 H2A histone family, member Z 
NM_006763 BTG family, member 2 
BC002802 suppressor of Ty 4 homolog 1 (S. cerevisiae) 
NM_001814 cathepsin C 
BE966236 ribonucleotide reductase M2 polypeptide 
NM_001168 baculoviral IAP repeat-containing 5 (survivin) 
NM_014669 nucleoporin 93kDa 
NM_021953 forkhead box M1 
NM_000295 
serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), 
member 1 
NM_002358 MAD2 mitotic arrest deficient-like 1 (yeast) 
BG170541 met proto-oncogene (hepatocyte growth factor receptor) 
NM_002996 chemokine (C-X3-C motif) ligand 1 
NM_014750 discs, large homolog 7 (Drosophila) 
NM_004523 kinesin family member 11 
NM_003686 exonuclease 1 
NM_003226 trefoil factor 3 (intestinal) 
NM_002452 nudix (nucleoside diphosphate linked moiety X)-type motif 1 
NM_013296 G-protein signalling modulator 2 (AGS3-like, C. elegans) 
NM_003536 histone 1, H3h 
NM_005951 metallothionein 1H 
NM_017522 low density lipoprotein receptor-related protein 8, apolipoprotein e receptor 
NM_003524 H2B histone family, member J 
NM_005952 metallothionein 1X 
AW149681 lysosomal associated protein transmembrane 4 beta 
U17496 
proteasome (prosome, macropain) subunit, beta type, 8 (large multifunctional 
protease 7) 
AF133425 tetraspan 1 
BC002649 histone 1, H1c 
BC000893 histone 1, H2bk 
AF321125 DNA replication factor 
AB000221 chemokine (C-C motif) ligand 18 (pulmonary and activation-regulated) 
AF098158 TPX2, microtubule-associated protein homolog (Xenopus laevis) 
D88357 cell division cycle 2, G1 to S and G2 to M 
AF133298 cytochrome P450, family 4, subfamily F, polypeptide 8 
AF033111 Homo sapiens Siva-2 mRNA, complete cds 
AF333388 Homo sapiens metallothionein 1H-like protein mRNA, complete cds 
AL582836 paternally expressed 10 
AA604621 MCM4 minichromosome maintenance deficient 4 (S. cerevisiae) 
NM_005953 metallothionein 2A 
BF974389 Mouse Mammary Turmor Virus Receptor homolog 1 
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AI991252 butyrophilin, subfamily 3, member A2 
AL120173 adenylate cyclase 1 (brain) 
AA927724 adenine phosphoribosyltransferase 
NM_003530 histone 1, H3d 
AI738662 homeo box HB9 
BG540628 Human active IgK chain from GM 607, V-kappa-2 region 
H53689 immunoglobulin lambda constant 2 (Kern-Oz- marker) 
NM_016185 hematological and neurological expressed 1 
NM_015895 geminin, DNA replication inhibitor 
NM_020188 DC13 protein 
NM_018131 chromosome 10 open reading frame 3 
NM_012177 F-box protein 5 
NM_006014 DNA segment on chromosome X (unique) 9879 expressed sequence 
NM_024745 SHC SH2-domain binding protein 1 
NM_018455 uncharacterized bone marrow protein BM039 
NM_017669 hypothetical protein FLJ20105 
NM_018063 helicase, lymphoid-specific 
NM_018846 kelch-like 7 (Drosophila) 
NM_031299 cell division cycle associated 3 /// cell division cycle associated 3 
BC003186 DNA replication complex GINS protein PSF2 
AB044548 eukaryotic translation initiation factor 4E binding protein 1 
AI859865 MCM4 minichromosome maintenance deficient 4 (S. cerevisiae) 
 
e) Low histologic grade (TuM1) 
NM_018422 pleckstrin and Sec7 domain containing 3 
NM_015310 pleckstrin and Sec7 domain containing 3 
NM_014456 programmed cell death 4 (neoplastic transformation inhibitor) 
NM_000662 N-acetyltransferase 1 (arylamine N-acetyltransferase) 
NM_014782 armadillo repeat containing, X-linked 2 
NM_006197 pericentriolar material 1 
NM_016337 Enah/Vasp-like 
NM_024788 hypothetical protein FLJ21062 
AU160041 chromosome 9 open reading frame 116 
AW970881 Clone IMAGE:5759947, mRNA 
AB050468 
leucine-rich repeats and immunoglobulin-like domains 1 /// leucine-rich repeats and 
immunoglobulin-like domains 1 
U56725 heat shock 70kD protein 2 
AJ001306 InaD-like protein 
NM_016640 mitochondrial ribosomal protein S30 
NM_000165 gap junction protein, alpha 1, 43kDa (connexin 43) 
AK022172 flavin containing monooxygenase 5 
AF047033 solute carrier family 4, sodium bicarbonate cotransporter, member 7 
AW242916 interleukin 6 signal transducer (gp130, oncostatin M receptor) 
NM_002065 glutamate-ammonia ligase (glutamine synthase) 
NM_005059 relaxin 2 (H2) 
NM_016210 g20 protein 
NM_004727 solute carrier family 24 (sodium/potassium/calcium exchanger), member 1 
NM_000169 galactosidase, alpha 
AF083108 sirtuin (silent mating type information regulation 2 homolog) 3 (S. cerevisiae) 
NM_017606 zinc finger protein 395 
BF593509 myosin binding protein C, slow type 
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AW242315 MRNA; cDNA DKFZp586M0723 (from clone DKFZp586M0723) 
AL512727 MRNA; cDNA DKFZp547P042 (from clone DKFZp547P042) 
T79953 KIAA0040 gene product 
AA824369 beta-transducin repeat containing 
BC000576 quinoid dihydropteridine reductase 
AA530995 Clone 24405 mRNA sequence 
NM_001045 solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 
    
 
MSA Standard Operating Protocol (SOP) 
RNA was extracted from frozen tissue using Trizol (Invitrogen, Carlsbad, CA), 
and RNA quality was assessed using an Agilent Bio Analyser (Agilent 
Technologies, Palo Alto, CA). Samples were processed for MSA profiling if there 
were clear 18S and 28S peaks with no minor peaks present, while samples 
without the 18S/28S peaks were regarded as degraded and excluded. Figure 20 
is a flowchart illustrating the standard operating protocol of the assay. 
 
Figure 20 Standard operating protocol for tumour sample preparation, RNA 











MSA Data Analysis  
Microarray Imager software (Combimatrix) was used to generate probe-level 
intensities. Individual MSAs were normalized by median-scaling the expression of 
control genes to the same value. To calibrate the MSAs, we generated MSA 
profiles for a training set of 16 tumours that had been previously profiled using 
Affymetrix U133plus Genechips (96). For each gene, we weighted the MSA 
probes by their strength of correlation to the Affymetrix expression data. Average-
linkage hierarchical clustering using Pearson correlation distance metrics was 
performed using CLUSTER and displayed using TREEVIEW software. Individual 
MSA profiles in the validation set were classified using Support Vector Machine 
algorithms (Genedata AG, Basel, Switzerland). The MSA gene expression data 




Quantitative RT-PCR for HER2gene expression.  
Total RNA was reverse transcribed using Superscript II Reverse Transcriptase 
(Invitrogen) and quantitative PCR was done using HER2/ERBB2 TaqMan probes 
(Hs00170433_m1) on a 7500 Real-time system (Applied Biosystems). TaqMan 
glyceraldehyde-3-phosphate dehydrogenase probes (Hs99999905_m1) were 
used as internal controls. All tumor samples were run in triplicates and compared 
against negative controls, which were either water controls or tissue samples 






Association of clinical variables between study groups were performed using chi2 
test, t test, one-way ANOVA, and Fisher’s exact tests. Kappa test was used to 
assess the agreement of the MSA with standard clinical tests such as IHC; 
logistic regression was used to assess the association of individual NPI 
components (tumour size, histologic grade, and lymph node status) with the MSA 
NPI-ES signature.  
 
Survival differences were plotted using Kaplan-Meier curves and Cox regression 
was used for the univariate analysis. Cox regression with stepwise forward 
hierarchical selection was used for the multivariate analysis assess if the 
expression signatures would contribute to the risk prediction in conjunction the 
clinically important variables, without any assumption on any underlying theory to 
base the model selection. The probability of inclusion into the multivariate model 
was 0.1. STATA10 (StataCorp.College Station, TX: Stata Corporation) was used 





Optimization of breast cancer MSA 
Using a standard operating protocol, we carried out several assays to assess the 
technical variability of the MSA, including replicate sample assays by the same 
operator, replicate sample assays by different operators, and replicate assays by 
different operators at different times. The assays were done both using RNA from 
breast cancer cell lines (MCF7) and primary tumours (Figure 21A). As shown in 
Table 22A, we attained good reproducibility in the MSA standard operating 
protocol with correlation coefficients ranging from 0.92 to 0.96 across the 
different assays (Table 22B). 
 
To assess long-term MSA reproducibility, a set of RNA samples was extracted 
from primary tumours, and four pairs of replicate hybridizations were done in 
which each member of a replicate pair was spaced 12 months apart. The 
replicate profiles also showed a high degree of concordance [correlation 
coefficients, 0.94 (0.85-0.99)], indicating that the MSA is likely to have good long-
term technical reproducibility. This level of consistency is similar to that achieved 
by other microarray platforms (25, 39) and suggests that the technical 
performance of the MSA is likely to be robust toward different operators and 
sample types. To calibrate the MSA against primary tumour samples, we profiled 
16 breast tumours (the ‘‘training set’’) previously assayed using standard 
Affymetrix GeneChip technology. Using a hierarchical clustering algorithm, we 
computed weights for each MSA probe such that the 16 training set tumours 
segregated into similar sample clusters (luminal/ER+, HER2, and basaloid) as 
the Affymetrix arrays (Figure 21B). 
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Table 22 Optimization of SOP and consistency of MSA 
(A) 
 
Day 1 Day 2 Day 3 Day 3a Operator B 
Day 1 - Operator A 1 
    
Day 2 - Operator A 0.94 1 
   





- Operator A 0.94 0.92 0.94 1 0.92 
Day 1  - Operator B 0.93 0.93 N.A. N.A. 1 
            
 
      
  
(B) 20020386 20020386 20020418 20020418 20021003 20021003 
 
Operator A Operator B Operator A Operator B Operator A Operator B 
20020386 Operator 
A 1 
     20020386 Operator 
B 0.94 1 
    20020418 Operator 
A 0.8 0.74 1 
   20020418 Operator 
B 0.81 0.74 0.98 1 
  20021003 Operator 
A 0.87 0.79 0.9 0.94 1 
 20021003 Operator 
B 0.87 0.78 0.89 0.94 1 1 
              
 
A) Correlation table comparing protocol consistency, inter-array and technical 
reproducibility from the MSA hybridizations performed by Operator A on day 1, 
2 and 3.  Inter-operator consistency was also demonstrated by comparison of 
hybridizations performed by both operator A and B on day 1. 
B) Correlation table comparing MSA hybridizations of three breast tumour 
samples performed by Operator A and Operator B. Inter-operator consistency 





 Figure 21 Optimization of MSA standard operating protocol 
 (A) Methods to assess MSA reproducibility using MCF-7 cell lines. Left, 
hybridization on two MSAs by operator A on day 1 and day 2; hybridization by 
operator B on day 1. Right: hybridization on two MSAs (3 and 3a) by operator A 
on day 3.  
(B) Hierarchical clustering showing molecular subtype classification (92 genes) of 
16 tumours (e.g., 980333 and 2000196) in the training set on MSAs (left) and 
Affymetrix U133-Plus arrays (right). The coloured lines represent the subtype 




Inter-operator Inter-array Technical 
replicates 
Split into 3 aliquots 
(1 st vial) 
Hybridization 
Operator A  
Day 1 
Operator B  
Day 1 
Operator A  
Day 2 
Hybridization 
(2 nd vial) 
Split into 2 aliquots 
Operator A  
Day 3       
Operator A  
Day 3a 
Fragmented MCF-7 cRNA Fragmented MCF-7 cRNA 














































































































































































Clinical features of patients and tumours 
 
Two hundred sixty-seven cases met our predefined inclusion criteria. All patients 
underwent surgical treatment, mastectomy, or breast conservation surgery and 
were given adjuvant therapy (chemotherapy, hormonal therapy, and chest wall 
radiotherapy) according to institutional practice guidelines. Pathological staging 
was available for all cases. After surgery, two thirds of patients had adjuvant 
chemotherapy and two thirds had adjuvant hormonal therapy based on the ER 
and/or progesterone immunohistochemical status at the time of surgery. 
 
On histopathologic assessment of tumor content, 38 tumors with no invasive 
ductal carcinoma were excluded, and a further 61 tumors were excluded for 
degraded RNA. There was insufficient RNA in three cases and, hence, these 
were also excluded. In total, 165 (62%) tumors were finally selected as the 
validation test set. The mean presence of invasive tumor was 72% (SD, 22%) 
and the RNA Bioanalyzer ratio was 1.5 (SD, 0.3) in the validation test set of 
165 cases. The clinicopathologic variables of the breast cancer patients and their 
tumors are summarized in Table 23. Importantly, there were no significant 
differences in these clinical variables between the training set, the ‘‘high-quality’’ 
validation test set, and the excluded cases (P > 0.05), suggesting that the 
populations are comparable. The mean age of patients in the validation set was 
56 +/- 12 (SD) years with 40% presenting with localized disease, which is similar 
to national demographic data for the local breast cancer population (120; 154). 
These results suggest that the validation set is likely to serve as a reasonably 




Table 23 Clinical features of the patients and tumours 
 
Training Test Excluded p 
Number of cases 16 165 102 
 Age (years) 
    Mean 52 56 59 0.953 
Range 30 - 79 33 - 83  35 – 87 
 SD 11 12 11 
 Age group (%) 
    < or = 54 years old 11 (69) 82 (50)  44 (43) 0.143 
> 54 years old 5 (31) 83 (50)  58 (57) 
 Tumour size (cm) 
    Mean 3.7 3.6 3.7 *0.545 
Range 1.6-6.0 0.6 - 12.5 0.3-12.0 
 SD 1.3 1.9 2 
 T stage** (%) 
    T1 4 (25) 36 (22) 13 (13) 0.452 
T2 10 (62) 102 (61) 72 (70) 
 T3 2 (13) 23 (14) 16 (16) 
 T4 0 (0) 5 (3) 1 (1) 
 Grade 
    1 3 (19) 18 (11) 10 (10) 0.597 
2 3 (19) 54 (32) 37 (36) 
 3 10 (62) 94 (57) 55 (54) 
 Lymph node status (%) 
   Negative 6 (38) 66 (40) 51 (50) 0.245 
Positive 10 (62) 100 (60) 51 (50) 
 
 
        
All Invasive ductal carcinoma of the breast. 
* comparison bewteen test and excluded cases only 
 ** T stage: TNM classification based on American Joint Committee on Cancer (AJCC) 
Cancer Staging Manual, Sixth Edition 
 
 
Validation of MSA expression signatures 
MSA classification and validation against Affymetrix Gene-Chip technology 
We generated MSA profiles for all 165 validation set tumors. Eighty-nine (54%) of 
the cases were luminal/ER+, 28 (17%) were HER2, and 29 (18%) were basaloid; 
19 (11%) were indeterminate. To compare the robustness of the MSA profiles to 
a different technology platform, RNA from a subset of the validation set tumors 
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(83 cases, 50%) was also applied to standard Affymetrix genome-wide arrays. Of 
the 83 cases, 9 (10%) were associated with indeterminate calls on either the 
MSA or Affymetrix platforms. Of the remaining 74 cases, there was a high  
concordance of 95% between both technologies, with the MSA classifying 51 
tumors as luminal/ER+, 12 as HER2, and 11 as basaloid, and the Affymetrix 
platform predicting 51 as luminal/ER+, 14 HER2, and 9 basaloid (Table 24). The 
k test confirmed that the level of observed concordance was highly significant (k 
= 0.89, P < 0.001). This result suggests that the signature genes on the MSA are 
likely to have good cross-platform transportability. 
 
Table 24 Concordance of molecular subtype classification between array 
platforms 
 
Affymetrix   
MSA Luminal(ER+) HER2 Basaloid 
Luminal(ER+) 50 1  
HER2 1 11  
Basaloid  
2 9 
        
kappa test 0.89, p<0.001 
Molecular subtype prediction (Luminal/ER+, HER2 and Basaloid) of 74 
tumors by MSA and Affymetrix arrays, 9 cases of indeterminate calls were 
not available for comparison. 
 
MSA validation against ER status 
Eighty-nine of 146 (61%) validation cases were classified as luminal/ER positive 
by the MSA and 57 cases as ER negative. A correlation to ER 
immunohistochemistry revealed a 90% concordance between the MSA and 
immunohistochemistry classifications (P < 0.001, k test; Table 4.3A), indicating a 
good correlation between gene expression and immunohistochemistry. Similar 
associations about breast tumor ER status have previously been reported (11). 
112 
 
To investigate the discrepant classifications, we retrieved paraffin-embedded 
tumor blocks for all 165 validation set cases from the hospital pathology archives 
and subjected these tissues to a repeat ER immunohistochemistry procedure; 
only 2 cases did not have remaining tissue for reassessment. The correlation of 
the repeat immunohistochemistry with the ER MSA remained good at 89% (P < 
0.001, k test). Of the 14 cases with discrepant immunohistochemistry and ER 
MSA classifications, 6 reassessments supported the ER MSA classification, with 
some tumors originally classified as ER+ by immunohistochemistry, now 
supporting an ER-negative immunohistochemistry classification and vice versa 
(Figure 22; Table 25). 
 
Table 25 Validation of our gene signatures (ER, ERBB2, NPI-ES and TuM1) on 
165 breast tumors using the customized microarrays. 
 
 
(A) ER status by Immunohistochemistry (IHC) 
MSA Signature ER+ 
 
ER- 






     (B) HER2 status by FISH FISH ratio 
 
FISH ratio 
 MSA Signature ratio < 2.2 
 
> or =2.2 






     (C) HER2 status by FISH* FISH ratio 
 
FISH ratio 
 MSA Signature ratio < 5 
 
> or = 5 






     (D) Nottingham Prognostic Index (NPI) 
NPI-ES NPI < 4 
 
NPI = or > 4  






     (E) Tumour Grade 
TuM1 1 2 3 
 High 15 16 14 Fisher's 
Low 2 22 20 0.002 
          




Figure 22 Reassessment of ER status by immunohistochemistry. 
 
Repeat immunohistochemistry for ER status in two immunohistochemistry and MSA discrepant 
cases. A and C, original immunohistochemistry; B and D, repeat immunohistochemistry. A and B, 
sample10619531: MSA Basal. C and D, sample 2000032: MSA luminal. A,original 
immunohistochemistry: 3+, 20% 
(positive); B, repeat immunohistochemistry:1+, 5%(negative); C, originalimmunohistochemistry: 
negative; D, repeat immunohistochemistry: 2+,15% (positive). Images produced using light 























     
      2000388 Neg Luminal 0 0 Neg 
2000032 Neg Luminal 2+ 15% Pos 
2001196 Neg Luminal 3+ 90% Pos 
20020163 Neg Luminal 3+ 30% Pos 
      (n=10) 
     
      11401764 Pos HER2 1-2+ 10% Borderline 
2000174 Pos Basal 2+ 5% Neg 
10619531 Pos Basal 1+ 5% Neg 
10860931 Pos Basal 2+ 5% Neg 
2000191 Pos Basal 2+ 25% Pos 
20020443 Pos Basal 2-3+ 90% Pos 
20020896 Pos Basal 3+ 90% Pos 
2000149 Pos HER2 2+ 50% Pos 
20020207 Pos HER2 3+ 80% Pos 
20020386 Pos HER2 3+ 50% Pos 
            
Pos: positive; Neg: negative. The original ER status was obtained from the histological report; positivity is 
defined by a combination of intensity and percentage of staining. 
 
Repeat IHC of 14 discrepant cases between ER MSA and IHC classifications. 
Repeat IHC corresponding to MSA predictions are in bold. 
 
MSA validation against HER2 receptor status 
Twenty-eight of 146 (19%) of cases were classified as HER2 positive by the MSA 
and the rest as HER2 negative. There was a good agreement of 76% between 
HER2 status by MSA and FISH using the established HER2/CEP FISH ratio 
cutoff of 2.2 recommended by the American Society of Clinical Oncology/ College 
of American Pathologists guidelines ( p < 0.001, k = 0.433; Table 25B). Only one 
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case did not have sufficient tissue for reassessment by FISH. Thus, there seems 
to be a strong positive correlation between MSA HER2 signature expression and 
high-level HER2 FISH positivity. Interestingly, when the tumours were divided 
into 2 groups: negative or low-level HER2 amplification (FISH ratio <5); and 
tumours with medium (FISH ratio 5-10) or high-level (FISH ratio >10) HER2 
amplification based on categories from the PathVysion kit  (155), we observed a 
further improvement in concordance between the HER2 FISH and MSA results 
from (76% to 89%) (k = 0.646, p < 0.001; Table 25C). To ask if this could be due 
to poor MSA sensitivity, we independently measured HER2 gene and protein 
expression in a subset of FISH-negative, low-level amplified, and high-level 
amplified samples by quantitative RT-PCR, a more sensitive method for assaying 
gene expression. We found that HER2 gene expression in the FISH-negative and 
low-level amplified samples were highly similar even by quantitative RT-PCR (p = 
0.53), whereas high-level amplified samples exhibited significantly elevated 
HER2 gene expression (p = 0.04 and p = 0.007, compared with FISH-negative 
and low-level amplified samples, respectively; Table 27A). At the protein level, > 
90% of low-level amplified cases showed absent or marginal 
(immunohistochemistry 1+) HER2 protein expression similar to FISHnegative 
samples (Figure 23B; Table 4.5). In contrast, two thirds of high-level amplified 
cases showed moderate (immunohistochemistry 2+) to strong 
(immunohistochemistry 3+) HER2 protein overexpression (Figure 23B; Table 
27B), chi2 test, P < 0.001). To confirm this finding, we subjected all available 
cases in the validation set to a repeat HER2 immunohistochemical assessment. 
The slides were scored and reviewed by two pathologists under current criteria 
and compared with FISH. Even with the increase in the sample size, our 
observation remained unchanged. It is noted that HER2 amplification in 
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immunohistochemistry-negative and immunohistochemistry 1+ cases has 
previously been reported in other series (17). These results suggest that the 
apparent bias of MSA HER2 predictions for high-level FISH amplifications is 
unlikely to be simply due to a lackof MSA sensitivity but may be due to certain 
low-level amplification tumors behaving more like FISH-negative samples.  
 
Figure 23 HER2 status by FISH, quantitative RT-PCR, and 
immunohistochemistry in non- amplified, low-level amplified, and high-amplified 
tumours. 
 
A, quantitative RT-PCR of 23 FISH-positive samples using HER2 TaqMan probes. P values were 
calculated using t test to compare mean HER2 expression.  B, D, and F, HER2 gene amplification 
by FISH (magnification X1,000); orange signals represent copies of HER-2 gene and green signals 
represent copies of chromosome 17. C, E, and G, HER2 protein expression by 
immunohistochemistry; images produced by light microscopy with the Olympus BX51 fitted with 
camera DP70 (magnification, X 400). B and C, sample 2000327, FISH ratio 1.1, 
immunohistochemistry-negative; D and E, sample 2001099, FISH ratio 2.8, immunohistochemistry-
negative; F and G, sample 2002015, FISH ratio 8.7, immunohistochemistry 3+.  
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Table 27 Correlation of HER2 expression by FISH with MSA and IHC 
  





 A. Gene Signature ratio <2.2 ratio ≥2.2 concordance ratio <5 ratio ≥5 concordance 
 
HER2- 86 31 76% 109 8 89% 
 
HER2+ 4 24 <0.001 8 20 <0.001 
        B. IHC Intensity 
      0 (Negative) 84 28 <0.001 107 5 <0.001 
1 (weak positive) 0 3 
 
1 2 
 2 (borderline) 4 7 
 
6 5 
 3 (strong positive) 1 15 
 
1 15 
                 
(A) HER2 expression signature correlation to FISH negative and FISH positive (cut-off 2.2). FISH medium-high 
level and low- and negative- level samples (cut-off 5).   (n=145, FISH was not performed for 1 case with insufficient 
tissue); B) Correlation of HER2 protein expression by IHC to HER2 FISH negative and FISH positive (cut-off 2.2); 
FISH medium-high level and low- and negative- level samples (cut-off 5). (n=142, IHC was not performed for 3 
cases with insufficient tissue). 
 
 
MSA validation against the NPI and low tumor grade 
The NPI is a clinicopathologic staging system that incorporates tumor size, tumor 
grade, and lymph node status for breast cancer prognostication. Fifty-two of 89 
(58%) luminal/ER+ cases were classified by the MSA as expressing high levels 
of the NPI-ES expression signature, whereas 37 cases were classified as NPI-ES 
negative. Using a previously defined NPI cutoff value of 4 (96). with lower NPI 
values indicating good prognosis and high NPI values indicating poor prognosis, 
a concordance of 67% between NPI-ES expression and NPI status (k = 0.316, P 
= 0.001; Table 4.3D) was observed. Of the individual NPI components, only 
histologic grade (P = 0.004) was significantly associated with NPI-ES expression 
in this set of tumors, whereas lymph node status (P = 0.103) and tumor size (P = 




Table 28 Association of the components of Nottingham Prognostic Index (NPI) 
with NPIES 
  Characteristic p 
Tumor size 0.096 
Lymph node status (positive or 
negative) 
0.103 
Histological grade (1, 2, or 3) 0.004 
    
* Univariate logistic regression  
 
 
This result validates the association between the NPI and NPI-ES in an 
independent patient population. The TuM1 expression signature was previously 
identified by our group as a potential biomarker for low histologic grade and 
predictor of tamoxifen response (153). Forty-five of 89 (51%) luminal/ER+ cases 
were classified as expressing high levels of the TuM1 expression signature, 
whereas 44 cases were classified as TuM1 negative. A comparison with 
histologic grade (modified Bloom-Richardson grading) revealed that 15 of 17 
(88%) grade 1 tumors exhibited high levels of TuM1 expression compared with 
30 of 72 grade 2 and 3 tumors (p = 0.002, Fisher’s exact test). These figures are 
consistent with our previous findings (153) and validate the association between 
TuM1 expression and tumor grade.  
 
The effect of archival protocol affects sample tissue quality 
Of the 267 cases that were initially evaluated for this study, 165 (62%) met our 
inclusion criteria and were profiled on the MSA, whereas the remaining cases 
were excluded. We examined the excluded samples and found a striking 
association between the likelihood of a sample being excluded and the year of 
archival. Specifically, whereas the percentage of excluded cases for either 
degraded RNA or lack of tumor content was 56% for samples archived in 2000, 
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this number was only 5% for samples archived from 2004, where only one 
sample (5%) was excluded for degraded RNA (Table 29). This finding is 
consistent with an improvement of archival protocol over the years. Moreover, a 
review of the 19 cases wherein the MSA produced indeterminate calls showed 
that the tissue had good tumor content (72%; SD, 25%) and good quality RNA 
(Bioanalyzer ratio, 1.5; SD, 0.3), indicating that the inability to classify these 
samples is likely not to be a result of poor tissue quality. Thus, while not ignoring 
the strong necessity for improving and standardizing protocols for tissue handling 
and preservation, these results suggest that our standard operating protocol for 
the MSA platform may have general applicability to the current clinical setting 
with a low frequency of sample loss. One obvious way to increase number of 
cases suitable for MSA profiling would be to inspect the tissue blockat the time of 
accrual to ensure adequacy of sampling. 
 
Table 29 Review of the Excluded Samples 
  Excluded cases   Test   Total 
 
No. (% by Yr) 
 











































                  
Total number of cases and the reasons of exclusion from the validation test set of cases 





Kaplan Meier Graphs for survival 
The patient follow-up in our validation series is a median of 7.3 years (SD, 2.6  
years) and disease-free survival period of 7.1 years (SD, 3.0 years). 
 
TuM1 signature 
Patients with luminal/ER+ tumors expressing high levels of the TuM1 signature 
were associated with significantly improved disease-free survival compared with 
patients with low-TuM1 expressing tumors (hazard ratio (HR), 0.24; p = 0.005; 
Figure 24). 
 












Kaplan-Meier analysis of the probability of remaining free of distant metastasis in patients 
with luminal/ ER+ subtype tumours only (n = 89). High expression ofTuM1 is represented 
by the black line and low expression of TuM1by the grey line. The HR of highTuM1to low 
TuM1and p values was calculated with the Cox-regression, with stepwise forward 




TuM1 signature No (%) Yes (%) Total 
Low 27 (61) 17 (39) 44 
High 38(84) 7 (16) 45 
Total 65 24 89 
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By Molecular signature and NPIES signature 
However, molecular and NPI-ES signature could not predict any survival 
difference in this validation set ( 
). 
 




   
Recurrence 
 
Molecular signature No (%) Yes (%) Total 
 
NPIES signature No (%) Yes (%) Total 
Luminal 65 (73) 24 (27) 89 
 
Low 26 (70) 11 (30) 37 
Basal 20 (69) 9 (31) 29 
 
High 39 (75) 13 (25) 52 
HER2 19 (68) 9 (32) 28 
 
Total 65 24 89 
Total 104 42 146 






Univariate and multivariate analysis  
In a univariate analysis involving patient age (</=54 or >54 years, representing 
premenopausal/perimenopausal and postmenopausal categories, respectively), 
tumor stage, lymph node status, histologic  grade, lymphovascular invasion, NPI, 
TuM1, and NPI-ES, age (p = 0.046), tumor stage (p = 0.015), grade (p = 0.083), 
and TuM1 (p = 0.01) were significant predictors of disease-free survival. However, 
a subsequent multivariate analysis of these variables with a probability of 
inclusion of 0.1, which also included the use of adjuvant chemotherapy (p= 
0.088), showed that only TuM1 (HR, 0.20; p = 0.019) remained as the only 
independent prognostic factor (Table 30). Notably, the use of adjuvant 
chemotherapy (HR, 0.7; p = 0.225) in this cohort did not significantly affect 
disease-free survival. Because patients in this validation set who had ER+ 
tumors were the recipients of antihormonal therapy, this result is consistent with 





Table 30 Univariate and multivariate analysis associating clinicopathologic 
factors with disease-free survival in Luminal/ER+ tumours (n=89). 
UNIVARIATE:  
    Variable HR p 95% CI 
Clinical 
    Tumour stage (TNM) 2.0 0.015* 1.1 3.6 
Age group 
    < or = 54 years 1 reference 
  > 54 years 2.0 0.046* 1.0 3.8 
Nottingham Prognostic Index (NPI) 
    NPI < 4 1 reference 
  NPI > or = 4 2.0 0.15 0.8 5.1 
Lymph nodes status (positive to negative) 2.0 0.188 0.7 5.5 
Histological Grade  
    Grade 1 1 reference 
  Grade 2 3.3 0.27 0.4 26.5 
Grage 3 6.1 0.083* 0.8 48.0 
LVI (pos vs neg) 1.8 0.201 0.7 4.6 
     Molecular 
    TuM1 
    low expression 1 reference 
  high expression 0.2 0.01* 0.1 0.7 
NPIES 
    high expression 1 reference 
  low expression 0.6 0.273 0.3 1.5 
     Treatment 
    Chemotherapy 0.5 0.088* 0.2 1.1 
Radiotherapy 1.2 0.648 0.5 3.1 
Hormonal therapy 0.5 0.25 0.2 1.6 
     MULTIVARIATE: 
    Model 1: stepwise forward hierachical 
selection 
    TuM1  0.2 0.019** 0.1 0.8 
Age > 54 years 1.8 0.212 0.7 4.6 
     Model 2: including adjuvant chemotherapy 
    Tum1 0.3 0.029** 0.1 0.9 
Age > 54 years 1.6 0.347 0.6 4.3 
Chemotherapy 0.7 0.382 0.3 1.7 
          
*p value < 0.1 selected into the multivariate model 
**p < 0.05 







Study 4 is a cross sectional type of design to produce a custom microarray to 
validate a set of microarray signatures previously discovered on a selected set of 
local subjects. Important factors in such studies include sensitivity and specificity 
of the platform, both inter and intra-assay reproducibility. Also important is 
knowledge of the degree of cross-platform agreement. 
 
Age at 54 years was used at the cut off for the menopausal status to exclude the 
peri-menopausal group from the menopausal group in this study. This 
categorization is different from the previous studies, and is the decision of the 
research groups, although ideally, it is preferable to use the same age threshold 
in the same thesis.  
 
Selection bias 
The cases selected were based on the availability of frozen tumour samples in 
the tissue repository. These tumours tended to be larger hence in a more 
advanced stage, but this is unlikely to contribute significantly to the internal 
validation of this study. The clinical characteristics were random, the training set 






The ability to classify the tumours accurately using the custom array is dependent 
on several factors:  
 Robustness of the signature 
 Quality of the tissue samples 
 Design of the custom array 
 Reproducibility and consistency of the assay  
 Specificity and sensitivity of assay  
 
The set of signatures used to design this custom array was based on prior 
discoveries. It important however, to note that this knowledge was based on a 
reliable microarray technology in the initial discovery experiments. These were 
validated using external datasets in prior studies but not in a local dataset. The 
cases were also selected based on strict selection criteria where there must be 
adequate tumour cells with full histological information as well as good quality 
RNA as this may result in misclassification.  
 
Design of the custom array was based on replicate gene probes for the selected 
gene in multiple replicates and control genes to improve specificity and sensitivity.  
This was also calibrated and correlated using the Affymetrix, an established 
technology which was used to discover the gene signatures. Replicate 
experiments using biological and experimental replicates were performed for 
protocol consistency, intra-array, inter-array and technical reproducibility by 
technologists specialized in each particular microarray labelling and hybridization 
protocol to ensure the MSA protocol was good. Correlation with standard clinical 
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tests such as IHC for ER and PR, as well as FISH and RT-PCR for HER2 was 
performed with the MSA. Additional efforts were made to reassess the ER and 
study the discrepancies 
. 
Confounding 
Ethnicity was not considered in this study, but unlike experiments to discover sets 
of genes associated with the biological phenomena of interest, the effect of 
ethnicity on the tumour biology is likely small for a validation study to assess  
tumour classification, with established subtypes (92–95), based on the 
microarray platforms (104) and ethnic populations (105), and the reproducibility 
of gene expression signature–based predictions has been confirmed in replicate 
experiments (106; 107). 
 
Custom multi-signature assay 
 
In the current treatment of breast cancer, lymph node status, tumour size and 
histologic grade, histologic tumour type, and lymphatic vascular invasion are the 
most prognostic factors available (156). The most widely prognostic tool used 
clinically is the TNM staging, where grade is still not included in the revision of 
the TNM staging system of breast cancer despite its prognostic value (157). 
Histopathological methods of classification such as immunohistochemistry (IHC) 
and fluorescent in situ hybridization (FISH) are routine for its predictive value for 
therapy with survival benefits. However, assessment of these parameters is 
associated with limits, including significant inter-observer variability and their 
reliance on measuring single biomarkers and hence the need to carry out 
multiple independent tests on the same tumour. Thus, there is a need to improve 
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existing breast tumour classification methods in terms of robustness, 
comprehensiveness, and efficiency for better prognostication. 
 
The primary objective of study 4 was to validate a series of gene expression 
signatures that we had previously described in our local Asian breast cancer 
population. These include signatures for molecular subtype classification 
(luminal/ER+, HER2, and basaloid), the NPI (NPI-ES), and low histologic grade 
(TuM1). The MSA was highly reliable with respect to several clinical variables, 
supporting the use of custom arrays to function as a potential adjunct to standard 
immunohistochemistry and FISH in clinical practice. One notable element was 
the decision to validate these signatures using a customized microarray platform 
as opposed to a generic genome-wide array as custom designed arrays have 
only been used in a few validation studies (100; 158; 159), and most of these 
have examined a single expression signature. In concept, the use of a focused 
array may be advantageous for the actual implementation of such devices in the 
clinical setting. First, limiting the array to informative genes may increase their 
cost effectiveness (e.g., by establishing multiplex arrays in which multiple patient 
samples are profiled on a single array). Second, having limited gene content may 
also prove useful in transporting these informative gene sets across other 
technology platforms that are superior to current solid-substrate arrays in terms 
of sensitivity, assay speed, and sample quantity (e.g., quantitative RT-PCR). 
Third, compared with standard assays, the MSA is able to assess multiple 
biomarkers in a single test. Currently, at least two or three independent assays 
(IHC for ER and HER2 and FISH for HER2) are required with each assay 
requiring different sets of technical protocols and reagents. The ability to achieve 
comparable accuracies of ER and HER2 classification using a single test and 
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technical protocol, coupled with the ability to also discern additional signatures 
(i.e., NPI-ES and TuM1), highlights the potential for such array platforms in the 
molecular diagnostic arena. 
 
The signatures and validation series were derived from a population of 
predominantly Chinese patients. Reports have described intriguing epidemiologic, 
clinical, and molecular differences in breast cancer between different ethnic 
groups (160). For example, whereas the peak of breast cancer incidence in 
Western populations occurs in the postmenopausal age group and is relatively 
rare among those <40 years of age, many Asian populations display a striking 
premenopausal incidence peak (33; 161; 162). This may be due to age-related 
differences in breast cancer risk factors like parity and body size for women of 
different ethnicities. At the metabolic and histopathologic level, ethnic differences 
in the levels of circulating sex steroid hormones (163) and differing frequencies of 
breast cancer histologic subtypes have also been reported (22). Furthermore, at 
least one report has observed distinct gene expression patterns associated with 
African American breast cancer (164), and recent discoveries have shown that 
lung cancers in Asian women are frequently mutated in the EGFR gene (165). 
Taken collectively, these observations support the need for considering how 
ethnicity might influence the performance of such molecular diagnostic assays; 
and to use a local gene signature instead of commercially available assays 
developed from tumours from Caucasian populations. 
 
One interesting subpopulation in this validation series involved tumours 
possessing low levels of HER2 FISH amplification. These cases tended to be 
immunohistochemistry negative for HER2 and the majority were luminal/ER+ by 
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the MSA. At present, trastuzumab (Herceptin) is clinically recommended in the 
adjuvant setting for HER2 FISH–positive samples. In this study, we observed a 
good concordance of 76% between HER2 MSA and FISH at the 2.2 threshold. 
However, the concordance further improved to 89% when the tumours were 
divided into negative/low positive (ratio <5) and medium-high level amplified 
categories (ratio >5). One possible explanation is that certain tumours with low-
level FISH positivity (ratio, 2.2-5) may behave more similarly to FISH-negative 
samples than to tumours with high-level amplification (ratio >5), with no protein 
significant expression. Supporting this, it was reported that in a large series of 
6,556 tissues analysed with HER2 immunohistochemistry and FISH, FISH 
amplification could be observed in HER2 immunohistochemistry-negative and 
immunohistochemistry 1+ cases (166). This observation as confirmed using three 
different independent assays: MSA HER2 expression signature, HER2 
quantitative RT-PCR, and HER2 protein immunohistochemistry. These results 
suggest that it may prove valuable for future studies to investigate the validity of 
raising the FISH ratio to >2.2, the threshold that is currently recommended.  
 
In the background where many current standard parameters used have 
limitations that there is a constant need to improve existing breast tumour 
classification methods in terms of robustness, comprehensiveness, and efficiency 
for better prognostication, that research such as this is undertaken. There are 
limitations of the MSA in terms of the technology as fresh frozen tissues were 
used instead of paraffin embedded samples, making the test cumbersome. We 
can overcome this as tissue can be collected fresh at surgery or biopsy, as we do 
for cancers such as lymphomas. Indeed if the signatures were merely equivalent, 
with no additional signatures, in addition to the cumbersome nature and high cost 
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for the gene expression analysis, the test is indeed not attractive and will be a 
significant limitation for clinical use. However, I would still argue on the potential 
benefits of: 
• The ability to achieve comparable accuracies of ER and HER2 
classification.  
• Be an adjunct for ER classification as reassessments by IHC 
supported the ER MSA classification providing a more accurate ER 
assessment.  
• Using a single test and technical protocol in replacement of separate 
tests with potential cost savings as the cost decreases  
• Coupling with the ability to also discern additional signatures (i.e., 
NPI-ES and TuM1) 
 
Future work could include looking at the use of paraffin-embedded tissue, 
refinement of the assay, use of other platforms as well as multiplex assays to 




The results demonstrate the reproducibility and robustness of the gene 
signatures on the MSA, with a simple operating protocol that can measure 
multiple biomarkers simultaneously (i.e., the standard ER and HER2 markers). In 
addition, the TuM1, a low-grade marker has prognostic implications. One 
potential weakness of this study is that the clinical follow-up is still in the early 
years and immature, and hence the long-term prognostic power of some 
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signatures cannot be conclusively assessed. Nevertheless, at least one signature 
(TuM1) was associated with improved survival, even in this interim analysis. 
Future work will involve assessing the long-term outcome of disease in our breast 
cancer patients and comparing them to similar outcome metrics in the United 





CHAPTER 7 CONCLUSIONS 
 
In this thesis, we demonstrated the following: 
1. Trends in breast cancer survival in Singapore compared to a western 
population of Stockholm which showed that the main difference in overall 
survival difference was due to the presentation of more advanced stage of 
breast cancer in Singapore. This advantage disappeared when survival was 
stratified by stage. 
2. We hypothesize that better economic status associated with increased 
awareness of the disease, better access to screening routines or healthcare 
quality and options, seen in Stockholm and in Singapore only in the later 
decade, offer the main explanation for the prognostic differences and 
similarities.  
3. Trends in breast cancer survival between ethnic groups in Singapore: 
Chinese, Malays and Indians were demonstrated. There were more 
premenopausal Malays presenting with breast cancer compared to the 
Chinese and Indians. They presented with a more advanced stage of disease 
and have poorer prognosis. Within the ethnic groups, there is a difference in 
stage distribution; stratified by stage, there is a difference in survival between 
the ethnic groups; and when taken together, stage and ethnicity were 
independent predictors. Ethnic difference and possibly factors related to 
ethnicity such as SES were likely reasons for this overall difference.  
4. The tumour biology in terms of ER, PR and HER2 were not different by 
ethnicity and hence is not a likely reason for survival difference between 
ethnicity; however, there was some difference in grade and LVI between 
ethnicity. Grade and LVI were correlated with ethnicity and likely contributed 
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to the survival difference. Nevertheless, tumour subtype, grade, LVI, stage 
and ethnicity were independent risk factors of death. Hence, other factors 
associated with ethnicity such as tumour biology other than subtype, 
response to treatment as well as cultural difference in seeking treatment 
could be contributory. 
5. There is a drive for a development of a single ideal prognostic test to provide 
the necessary information for treatment; and advances in the molecular high 
throughput technology has led to an explosion of its utility to discover such a 
test, especially one which could possibly decipher the genetic and ethnic 
differences. This journey to design and validate a custom multi-signature 
assay (MSA) is a significant step forward as a proof of point in a local 
Singaporean context, but further work is needed. 
 
In this era of personalized medicine (also termed personalized genomics, 
genomic medicine, or theranostics), the application of patient-specific profiles, 
incorporating genetic and genomic data as well as clinical and environmental 
factors, to assess individual risks and tailor prevention and disease management 
strategies has gained popularity and significance. Translating these results to 
public health would include the following:  
 Scientific discovery of ethnic driven differences in breast cancer biology in 
Singapore e.g., tumours in Malay women 
 Customize treatment plans that could encompass targeted 




 Targeted health education and planning, development of support and 
financial help groups for those most at risk, e.g., amongst the Malays with 
lower SES 
 Targeted recommendations for lifestyle modifications for the modifiable 
risk factors such as adolescent pregnancies which could affect breast 
cancer biology and prognosis 
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